Official Protocol Title:
NCT number:                [STUDY_ID_REMOVED]
Document Date:            21-Jul-2022             
A Randomized Clinical Study to Evaluate the
Safety and Tolerability of MK-
8189 in Participants with Alzheimer’s Disease
with or without Symptoms of Agitation-
Aggression and/or Psychosis

PRODUCT: MK-8189  1
PROTOCOL/AMENDMENT NO.: 017-04
MK-8189 -017-04FINAL PROTOCOL 21-JUL-2022
Title Page
THIS PROTOCOL AMENDMENT AND ALL OF THE INFORMATION RELATING 
TO IT ARE CONFIDENTIAL AND PROPRIETARY PROPERTY OF MERCK 
SHARP & DOHME LLC , RAHWAY, NJ, [LOCATION_003] (MSD) .
Protocol Title: A Randomized Clinical Study to Evaluate the Safety and Tolerability of MK -
8189 in Participants with Alzhe imer’s Disease with or without Symptoms of Agitation -
Aggression and/or Psychosis
Protocol Number: 017-04
Compound Number: MK-8189
Sponsor Name:
[CONTACT_19519] & Dohme LLC
(hereafter called the Sponsor or MSD)
Legal Registered Address:
[ADDRESS_111367], NJ [ZIP_CODE] [LOCATION_003]
Regulatory Agency Identifying Number(s):
IND 159736
Approval Date: [ADDRESS_111368]: MK-8189  2
PROTOCOL/AMENDMENT NO.: 017-04
MK-8189 -017-04FINAL PROTOCOL 21-JUL-2022
Sponsor Signatory
Typed Name:
[CONTACT_1641]:Date
Protocol -specific Sponsor c ontact information can be found in the Investigator Study
File Binder (or equivalent).
Investigator Signatory
I agree to conduct this clinical study in accordance with the design outlined in this protocol 
and to abide by [CONTACT_19373].
Typed Name:
[CONTACT_1641]:Date
08CG6Z
PRODUCT: MK-8189  3
PROTOCOL/AMENDMENT NO.: 017-04
MK-8189 -017-04FINAL PROTOCOL 21-JUL-2022
DOCUMENT HISTORY
Document Date of Issue Overall Rationale
Amendment 04 21-JUL- 2022 Exclusion criteri on#[ADDRESS_111369] dosing 
regimen to be evaluated has been modi fied such that participants will be 
titrated up to MK -8189 16 mg/placebo as opposed to initially titrating 
participants up to MK -8189 24 mg/placebo.  
Amendment 01 28-JAN-2022 Added the Columbia Suicide Severity Rating Scale (C -SSRS) to every visit.
Original Protocol 10- DEC -[ADDRESS_111370]: MK-8189  4
PROTOCOL/AMENDMENT NO.: 017-04
MK-8189 -017-04FINAL PROTOCOL 21-JUL-2022
PROTOCOL AMENDMENT SUMMARY OF CHANGES
Amendment: 04
Overall Rationale for the Amendments:
Exclusion criteri on#22 was modified to clarify the use of permitted prescribed medications ,which could generate a positive UDS ,is 
not exclusionary.
Summary of Changes Table:
Section # and Name [CONTACT_11029]  
5.2 Exclusion Criteria The following bolded statement was 
added to Exclusion #22:  P articipants 
must have a negative UDS (with the 
exception of cannabis and/or prescribed 
medications permitted at the discretion 
of the PI [INVESTIGATOR_80336] )prior to 
randomization.As the intention of this criterion is to exclude 
participants using illicit drugs or participant s with a 
history of drug abuse, participants may be included if 
using permitted prescribed medications which generate 
a positive UDS.  
5.1 Inclusion Criteria Inclusion #1 and Inclusion #9 were 
updated to include clarifications per PCL 
#1.N/A
6.[ADDRESS_111371]: MK-8189  5
PROTOCOL/AMENDMENT NO.: 017-04
MK-8189 -017-04FINAL PROTOCOL 21-JUL-2022
Section # and Name [CONTACT_11029]  
[IP_ADDRESS] Resting Vital Signs Wording was updated to clarify Day 1 
predose vital signs should be taken within
3 hours prior to dosing. The language is now consistent with the Schedule of 
Activities footnote.
10.2 Appendix 2: Clinical 
Laboratory TestsA sen tence was added to indicate routine 
urinalysis and urine pregnancy tests will 
be done locally at the site.The central lab vendor will only be sent urinalysis 
samples if a microscopic examination is required.
08CG6Z
PRODUCT: MK-8189  6
PROTOCOL/AMENDMENT NO.: 017-04
MK-8189 -017-04FINAL PROTOCOL 21-JUL-2022
Table of Contents
DOCUMENT HISTORY ........................................................................................................ 3
PROTOCOL AMENDMENT SUMMARY OF CHANGES ............................................... 4
1 PROTOCOL SUMMARY ............................................................................................ 14
1.1 Synopsis ................................................................................................................. 14
1.2 Schema .................................................................................................................. 17
1.3 Schedule of Activities........................................................................................... 18
2 INTRODUCTION .......................................................................................................... 22
2.1 Study Rationale ....................................................................................................22
2.2 Background .......................................................................................................... 22
2.2.1 Pharmaceutical and Therapeutic Background ............................................. 22
2.2.2 Preclinical and Clinical Studies ...................................................................23
2.2.3 Ongoing Clinical Studies ............................................................................. 24
[IP_ADDRESS] Protocol 011 ....................................................................................... 24
[IP_ADDRESS] Protocol 012 ....................................................................................... 27
[IP_ADDRESS] Protocol 015 ....................................................................................... 28
[IP_ADDRESS] Protocol 008 ....................................................................................... 28
2.3 Benefit/Risk Assessment ...................................................................................... 28
3 HYPOTHESES, OBJECTIVES, AND ENDPOINTS ................................................ 29
4 STUDY DESIGN ............................................................................................................ 30
4.1 Overall Design ......................................................................................................30
4.2 Scientific Rationale for Study Design ................................................................ .31
4.2.1 Rationale for Endpoints ............................................................................... 32
[IP_ADDRESS] Efficacy Endpoints ............................................................................. 32
[IP_ADDRESS] Safety Endpoints ................................................................................ 32
[IP_ADDRESS] Pharmacokinetic Endpoints ............................................................... 33
[IP_ADDRESS] Planned Exploratory Biomarker Research .........................................33
[IP_ADDRESS].1 Planned Genetic Analysis ........................................................ 33
[IP_ADDRESS] Future Biomedical Research .............................................................. 33
4.2.2 Rationale for the Use of Comparator/Placebo ............................................. 34
4.2.3 Rationale for Suicidal Ideation and Behavior Monitoring ........................... 34
4.3 Justification for Dose ........................................................................................... 34
4.3.1 Starting Dose for This Study ........................................................................34
4.3.2 Maximum Dose/Exposure for This Study ................................................... [ADDRESS_111372]: MK-8189  7
PROTOCOL/AMENDMENT NO.: 017-04
MK-8189 -017-04FINAL PROTOCOL 21-JUL-2022
4.4.1 Clinical Criteria for Early Study Termination ............................................. 36
5 STUDY POPULATION ................................................................................................ 36
5.1 Inclusion Criteria ................................................................................................ .36
5.2 Exclusion Criteria ................................................................................................ 39
5.3 Lifestyle Considerations ...................................................................................... 41
5.3.1 Meals and Dietary Restrictions ....................................................................41
[IP_ADDRESS] Diet Restrictions................................................................................. 41
[IP_ADDRESS] Fruit Juice Restrictions ......................................................................42
5.3.2 Caffeine, Alcohol, and Tobacco Restrictions .............................................. 42
[IP_ADDRESS] Caffeine Restrictions .......................................................................... 42
[IP_ADDRESS] Alcohol Restrictions ........................................................................... 42
[IP_ADDRESS] Tobacco Restrictions .......................................................................... 42
5.3.3 Activity Restrictions .................................................................................... 42
5.4 Screen Failures .....................................................................................................42
5.5 Participant Replacement Strategy ......................................................................42
6 STUDY INTERVENTION ............................................................................................ 43
6.1 Study Intervention(s) Administered ...................................................................43
6.2 Preparation/Handling/Storage/Accountability ................................................. 45
6.2.1 Dose Preparation .......................................................................................... 45
6.2.2 Handling, Storage, and Accountability ........................................................ 45
6.3 Measures to Minimize Bias: Randomization and Blinding .............................. 46
6.3.1 Intervention Assignment .............................................................................. 46
6.3.2 Stratification ................................................................................................ .46
6.3.3 Blinding ........................................................................................................46
6.4 Study Intervention Compliance .......................................................................... 47
6.5 Concomitant Therapy .......................................................................................... 47
6.5.1 Rescue Medications and Supportive Care ................................................... 48
6.6 Dose Modifica tion (Escalation/Titration/Other) ............................................... [ADDRESS_111373]: MK-8189  8
PROTOCOL/AMENDMENT NO.: 017-04
MK-8189 -017-04FINAL PROTOCOL 21-JUL-2022
8.1.1 Informed Consent ......................................................................................... 52
[IP_ADDRESS] General Informed Consent ................................................................ .52
[IP_ADDRESS] Consent and Collection of Specimens for Future Biomedical 
Research ............................................................................................. 53
8.1.2 Inclusion/Exclusion Criteria ........................................................................[ADDRESS_111374] .....................................................................53
8.1.4 Medical History ........................................................................................... 53
8.1.5 Prior and Concomitant Medications Review ............................................... 53
[IP_ADDRESS] Prior Medications ............................................................................... 53
[IP_ADDRESS] Concomitant Medications ..................................................................53
8.1.6 Assignment of Screening Number ............................................................... 54
8.1.7 Assignment of Treatment/Randomization Number .....................................54
8.1.8 Study Intervention Administration .............................................................. 54
[IP_ADDRESS] Timing of Dose Administration ......................................................... 54
8.1.9 Discontinuation and Wit hdrawal ................................................................ .55
[IP_ADDRESS] Withdrawal From Future Biomedical Research ................................ 55
8.1.10 Participant Blinding/Unblinding ..................................................................55
8.1.11 Calibration of Equipment ............................................................................. 56
8.1.12 Domiciling (optional) ................................................................................... 56
8.2 Efficacy Assessments ........................................................................................... 57
8.3 Safety Assessments ............................................................................................... 57
8.3.1 Physical Examinations ................................................................................. 57
8.3.2 Vital Signs ....................................................................................................57
[IP_ADDRESS] Resting Vital Signs ............................................................................ 57
[IP_ADDRESS] Orthostatic Vital Signs .......................................................................58
8.3.3 Electrocardiograms ...................................................................................... 58
8.3.4 Clinical Safety Laboratory Assessments ..................................................... 59
8.3.5 Pregnancy Testing ........................................................................................ 59
8.3.6 Suicidal Ideation and Behavior Monitoring ................................................. 60
[IP_ADDRESS] Clinical Assessments for Suicidal Ideation and Behavior 
Monitoring ......................................................................................... [ADDRESS_111375]: MK-8189  9
PROTOCOL/AMENDMENT NO.: 017-04
MK-8189 -017-04FINAL PROTOCOL 21-JUL-2022
8.4 Adverse Events, Serious Adverse Events, and Other Reportable Safe ty 
Events .................................................................................................................... 61
8.4.1 Time Period and Frequency for Collecting AE, SAE, and Other 
Reportable Safety Event Information .......................................................... 62
8.4.2 Method of Detecting AEs, SAEs, and Other Reportable Safety Events ......64
8.4.3 Follow -up of AE, SAE, and Other Reportable Safety Event Information ...64
8.4.4 Regulatory Reporting Requirements for SAE ............................................. 64
8.4.5 Pregnancy and Exposure During Breastfeeding .......................................... 65
8.4.6 Disease -related Events and/or Disease -related Outcomes Not Qualifying 
as AEs or SAEs ............................................................................................ [ADDRESS_111376] ............................................................................ 65
8.5 Treatment of Overdose ........................................................................................ 65
8.6 Pharmacokinetics ................................................................................................ .66
8.6.1 Blood Collection for Plasma MK- 8189 and/or Metabolites Assay ............. 66
8.6.2 Blood Collection for Plasma Donepezil Assay ............................................ 66
8.6.3 Blood Collection for Plasma Memantine Assay.......................................... 66
8.7 Pharmacodynamics .............................................................................................. 66
8.8 Biomarkers ........................................................................................................... 66
8.8.1 Planned Genetic Analysis Sample Collection.............................................. 66
8.8.2 Exploratory Plasma Biomarkers for Alzhe imer’s Disease Diagnosis 
Sample Collection ........................................................................................ 67
8.9 Future Biomedical Research Sample Collection ............................................... 67
8.10 Visit Requirements ............................................................................................... 67
8.10.1 Trial Partner/Caregiver Participation ........................................................... 67
8.10.2 Screening (Visit 1) ....................................................................................... 67
8.10.3 Baseline (Visit 2) ......................................................................................... 68
8.10.4 Intervention Period Visit (Visits 3 -9).......................................................... 68
8.10.5 Discontinued Participants Continuing to be Monitored in the Study .......... 68
8.10.6 Poststudy (Visit10) ....................................................................................... 69
8.10.7 Study Design/Dosing/Procedures Modifications Permitted Within 
Protocol Parameters ..................................................................................... 69
9 STATISTICAL ANALYSIS PLAN ............................................................................. 70
9.1 Statistical Analysis Plan Summary .....................................................................70
9.2 Responsibility for Analyses ................................................................................. 70
9.3 Hypotheses/Estimation ........................................................................................ [ADDRESS_111377]: MK-8189  10
PROTOCOL/AMENDMENT NO.: 017-04
MK-8189 -017-04FINAL PROTOCOL 21-JUL-2022
9.8 Multiplicity ........................................................................................................... 73
9.9 Sample Size and Power Calculations ................................................................ .73
10 SUPPORTING DOCUMENTATION AND OPERATIONAL 
CONSIDERATIONS .....................................................................................................74
10.1 Appendix 1: Regulatory, Ethical, and Study Oversight Considerations ........[ADDRESS_111378] for Clinical Trials ............................................................. 74
10.1.2 Financial Disclosure ..................................................................................... 76
10.1.3 Data Protection ............................................................................................. 77
[IP_ADDRESS] Confidentiality of Data ......................................................................77
[IP_ADDRESS] Confidentiality of Participant Records ............................................... 77
[IP_ADDRESS] Confidentiality of IRB/IEC Information ............................................ 77
10.1.4 Publication Policy ........................................................................................ 78
10.1.5 Compliance with Study Registration and Results Posting Requirements ...78
10.1.6 Compliance w ith Law, Audit, and Debarment ............................................ 78
10.1.7 Data Quality Assurance ............................................................................... 79
10.1.8 Source Documents ....................................................................................... 80
10.1.9 Study and Site Closure ................................................................................. 80
10.2 Appe ndix 2: Clinical Laboratory Tests .............................................................. 81
10.3 Appendix 3: Adverse Events: Definitions and Procedures for Recording, 
Evaluating, Follow -up, and Reporting ............................................................... 83
10.3.1 Definition of AE .......................................................................................... 83
10.3.2 Definition of SAE ........................................................................................ 84
10.3.3 Additional Events Reported ......................................................................... 85
10.3.4 Recording AE and SAE ............................................................................... 85
10.3.5 Reporting of AEs, SAEs, and Other Reportable Safety Events to th e 
Sponsor ........................................................................................................89
10.4 Appendix 4: Medical Device and Drug -device Combination Products: 
Product Quality Complaints/Malfunctions: Definitions, Recording, and 
Follow -up.............................................................................................................. 90
10.5 Appendix 5: Contraceptive Guidance ................................................................ 91
10.5.1 Defini tions....................................................................................................91
10.5.2 Contraception Requirements ........................................................................92
10.6 Appendix 6: Collection and Management of Specimens for Future 
Biomedical Research ............................................................................................ 93
10.7 Appendix 7: Country -specific Requirements .................................................... 98
10.8 Appendix 8: Blood Volume Table ......................................................................99
10.9 Appendix 9: Algorithm for Assessing Out of Range Laboratory Values .....100
10.10 Appendix 10: General (Full) and Targeted Neurological Exam ................... 101
10.11 Appendix 11: Abbreviations ............................................................................. [ADDRESS_111379]: MK-8189  11
PROTOCOL/AMENDMENT NO.: 017-[ADDRESS_111380]: MK-8189  12
PROTOCOL/AMENDMENT NO.: 017-[ADDRESS_111381]: MK-8189  13
PROTOCOL/AMENDMENT NO.: 017-[ADDRESS_111382]: MK-8189  14
PROTOCOL/AMENDMENT NO.: 017-04
MK-8189 -017-04FINAL PROTOCOL 21-JUL-2022
1 PROTOCOL SUMMARY
1.1 Synopsis
Protocol Title: A Randomized Clinical Study to Evaluate the Safety and Tolerability of MK -
8189 in Participants with Alzheimer’s Disease with or without Symptoms of Agitation-
Aggression and/or Psychosis
Short Title: MK-8189 Safety and Tolerability in Participants with Alzheimer’s Disease with 
or without Symptoms of Agitation -Aggression and/or Psychosis
Acronym: N/A
Hypotheses, Objectives ,and Endpoints :
There are no hypotheses for this study.
In male or female participants with Alzheimer’s Disease with or without symptoms of 
agitation- aggression and/or psychosis.
Objectives Endpoints
Primary
•To evaluate thesafety and tolerability of 
multiple ascending doses of MK -8189 in 
participants with Alzheimer’s Disease 
with or without symptoms of agitation -
aggression and/or psychosis•Adverse events
•Adverse experiences leading to 
discontinuation of study intervention
Secondary
•Not applicable
08CG6Z
PRODUCT: MK-8189  15
PROTOCOL/AMENDMENT NO.: 017-04
MK-8189 -017-04FINAL PROTOCOL 21-JUL-2022
Overall Desig n:
Study Phase Phase 1
Primary Purpose Treatment
Indication Neuropsychiatric Symptoms in Dementia
Population Male and f emale participants, 65-85years of age ,
inclusive, with clinically probable Alzheimer’s Disease
with or without symptoms of agitation- aggression and/or 
psychosis 
Study Type Interventional
Intervention Model Parallel
This is a multi- sitestudy.
Type of Control Placebo
Study Blinding Double -blind
Blinding Roles Investigator, Care Provider ,Participants or Subjects
Estimated Duration of Study The Sponsor estimates that the study will require 
approximately [ADDRESS_111383] 
participant (or their legally acceptable representative) 
provides documented informed consent until the last 
participant’s last study- related contact .
Number of Participant s:
Up to approximately 28participants will be allocated/r andomized such that at least 16 
evaluable participants complete the study as described in Section 9.
Note: Greater than [ADDRESS_111384]: MK-8189  16
PROTOCOL/AMENDMENT NO.: 017-04
MK-8189 -017-04FINAL PROTOCOL 21-JUL-2022
Intervention Groups and Du ration :
Intervention 
Group sInterven-
tion Group 
Name [CONTACT_100942] i-
strationRegimen/ Treatment 
Period/ Vaccination 
Regimen Use
Active MK-8189 4 mg & 12 mg QD OralTitration 1
4 mg x 2 tablets 
Days 1 -3; 
4 mg x 1 tablet & 
12 mg x 1 tablet 
Days 4 -28
Titration 2
4 mg x 2 tablets 
Days 1 -3; 
4 mg x 1 tablet & 
12 mg x 1 tablet 
Days 4-6;
12 mg x 2 tablets
Days 7 -28
Titration 3
4 mg x 1 tablet 
Days 1 -3;
4 mg x 2 tablets
Days 4 -6; 
4 mg x 1 tablet & 
12 mg x 1 tablet 
Days 7 -9; 
12 mg x 2 tablets
Days 10-28Experi -
mental 
Treatment
Placebo Placebo 0 mg QD OralTitration 1 & 2
2 tablets
Days 1 -28
Titration 3
1 tablet
Days 1 -3;
2 tablets
Days 4 -28Control
Abbreviations:
QD=Once aday
Total 
Number of 
Intervention 
Groups/
Arms2
Duration of 
ParticipationEach participant will participate in the study for approximately 3months 
from the time the participant provides documented informed consent 
through the final contact. After a screening phase of [ADDRESS_111385]: MK-8189  17
PROTOCOL/AMENDMENT NO.: 017-04
MK-8189 -017-04FINAL PROTOCOL 21-JUL-2022
Study Governance Committees:
Executive Oversight Committee No
Data Monitoring Committee No
Clinical Adjudication Committee No
Insert Other Oversight Committee No
Study governance considerations are outlined in Appendix 1.
Study Accepts Healthy Volunteers :No
A list of abbreviations is in Appendix 11.
1.[ADDRESS_111386]: MK-8189  18
PROTOCOL/AMENDMENT NO.: 017-04
MK-8189 -017-04FINAL PROTOCOL 21-JUL-2022
1.3 Schedule of Activities
Screening Baseline Intervention Poststudya
Visit 1 2 3 4 5 6 7 8 9l10
Scheduled Visit Day plus 
Window Up to -42 -5 to -3 1 4 7 10j14±121±128+1LD+14 +2
Administrative Procedures
Informed Consent –Study 
ParticipantX Section 8.1.1 .1
Informed Consent –Trial 
PartnerX Section 8.1.[ADDRESS_111387] X Section 8.1.3
Inclusion /Exclusion Criteria X XSection 5.1 & Section 5.2
Specific criteria may be reviewed 
before randomization
Medical History (includes 
psychiatric history and 
substance usage)XSubstances: Drugs, alcohol, tobacco, and 
caffeine
Section 8.10.2
Prior /Concomitant Medication 
ReviewX----------------------------------------------------------------------------------- X Section 6.5 , Section 8.10.2
Assignment of 
Treatment/Randomization 
NumberX
Study Intervention 
Administrationb X--------------------------------------------- XThe last dose will be on Day 28 regardless
of the Study D ay Visit 9 falls on.
Study Intervention 
Dispensing /ReviewX X X X X X XCollect prior medication bottle before 
dispensing new one.
Study Intervention Diary
Dispensing /ReviewX X X X X X XReview diary upon participants return to 
the CRU.
Daily Phone CallcX--------------------------------------------- X
Optional Domiciling X--------------------------------------------- X See Section 8.1.[ADDRESS_111388]: MK-8189  19
PROTOCOL/AMENDMENT NO.: 017-04
MK-8189 -017-04FINAL PROTOCOL 21-JUL-2022
Screening Baseline Intervention Poststudya
Visit 1 2 3 4 5 6 7 8 9l10
Scheduled Visit Day plus 
Window Up to -42 -5 to -3 1 4 7 10j14±121±128+1LD+14 +2
Weight X X X BMI to be calculated only at Screening
Full Neurological Exam X X Section 10.10
Targeted Neurological ExamdX X X X X Section 10.10
Vital Signs ( pulse rate, blood 
pressure)e, f X X X X X X X X X Section [IP_ADDRESS]
Orthostatic Vital Signs ( pulse
rate, blood pressure)e X X X X X X X X X Section [IP_ADDRESS]
Vital Signs ( respi[INVESTIGATOR_697], 
body temperature)e X X X X X X X Section [IP_ADDRESS]
12-lead ECGe, fX X X X X X X Section 8.3.[ADDRESS_111389] (as 
needed in WOCBP only)X Section 5.1 & Section 8.3.[ADDRESS_111390] (as 
needed in WOCBP Only)X X X X X X Section 5.1 & Section 8.3.5
Serum FSH (as need in 
WONCBP only)X
HIV, Hepatitis B and C Screen 
(per site SOP)X
UDS/BDS (per site SOP) X X
Laboratory Safety Tests
(hematology, chemistry, 
urinalysis)gX X X X X X X Section 10.2
Columbia Suicide Severity 
Rating Scale (C -SSRS) –
Baseline VersionX Section 8.3. 6.1
Columbia Suicide Severity 
Rating Scale (C -SSRS) –Since 
Last Assessment VersiondX X X X X X X X X Section 8.3. 6.1
Neuropsychi atric Inventory
(NPI)d,h X X Section 8.3. 10& Section 8.10. 2
Mini Mental State Examination
(MMSE -2)d X X Section 8.3. [ADDRESS_111391]: MK-8189  20
PROTOCOL/AMENDMENT NO.: 017-04
MK-8189 -017-04FINAL PROTOCOL 21-JUL-2022
Screening Baseline Intervention Poststudya
Visit 1 2 3 4 5 6 7 8 9l10
Scheduled Visit Day plus 
Window Up to -42 -5 to -3 1 4 7 10j14±121±128+1LD+14 +2
Rosen -Modified Hachinski 
Ischemic Score (MHIS)X Section 8.3. 8
Barnes Akathisia Rating Scale
(BARS )d,i X X X X X XiSection 8.3.1 1
Abnormal Involuntary 
Movement Scale (AIMS)d, i X X X X X XiSection 8.3.1 1
Simpson Angus Scale (SAS)d, iX X X X X XiSection 8.3.1 1
AE/SAE review X---------------------------------------------------------------------------------- X
Pharmacokinetics
Blood for Plasma MK -8189 
and/or Metabolites AssayX X X X XOn days noted, 2 b lood samples will be 
collected :
1) prior to dosing (fasted)  
2) 2-[ADDRESS_111392] dos e
Note: If Visit 9 occurs on Day 29, , only 1
blood sample will be collected as there 
will be no dose on this day.
Blood for Plasma Donepezil
Assayk X X X X X Blood collected prior to dosing (fasted).
Blood for Plasma Memantine 
Assayk X X X X X Blood collected prior to dosing (fasted)
Biomarkers
Blood for Exploratory Plasma 
Biomarkers for AD DiagnosisX See Section 8. 8.[ADDRESS_111393]: MK-8189  21
PROTOCOL/AMENDMENT NO.: 017-04
MK-8189 -017-04FINAL PROTOCOL 21-JUL-2022
Screening Baseline Intervention Poststudya
Visit 1 2 3 4 5 6 7 8 9l10
Scheduled Visit Day plus 
Window Up to -42 -5 to -3 1 4 7 10j14±121±128+1LD+14 +2
AE=adverse event; BDS=blood drug screen; C -SSRS=Columbia -Suicide Severity Rating Scale; DNA=deoxyribonucleic acid; ECG=electrocardiogram; FBR=future biomedical 
research; FSH=follicle stimulating hormone; hCG=human chorionic gonadotropin; ID=identification; SAE=serious adverse event; SOP=standard operating procedure; 
UDS= urine drug screen ; VS=vital signs; WOCBP=women of childbearing potentia l; WONCBP=women of nonchildbearing potential
a. Poststudy visit procedures should also be performed for participants who discontinued early from study intervention.
b.QD dosing at approximately the same time each morning (Days 1 -28)either in the CRU or at home. During scheduled CRU visits, participants should be 
administered study intervention fasted in the CRU. At home study intervention administration willbewith or without food and will be recorded in study 
intervention diar y by [CONTACT_2299]/trial partner .Participants wil l be supervised for at least [ADDRESS_111394] administration of each study intervention titration (see Section 8.1.8) .
c.While participants are outpatient, s ite staff willcall participants daily to check study administration compliance, review AEs, and remind participants of
their next scheduled visit (if applicable) .
d.Collected after dosing and an optional light breakfast on study treatment administration days.
e.Collected prior to dosing on study treatment administration days .
f.Vital sign measurements at Screening will be taken in triplicate. Day [ADDRESS_111395] washout of prior antipsychotic treatment at Screening, the NPI [INVESTIGATOR_100880] a minimum 2 -week 
washout or 5 half -lives, whichever is longer.
i.Poststudy assessment required only if clinically meaningful changes on Day 28 .
j.Visit 6 ( Day 10 ) will only occur for Titration 3. 
k.Sample will only be taken for participants currently taking donepezil and/or memantine.
l.Every effort should be made to have participants return for Visit [ADDRESS_111396] all Visit 9 
assessments completed.  Participants will not be dosed on Day 29.
m. This sample will be drawn for CYPC29 and for planned analysis of the association between genetic variants in DNA and drug response. If the IRB/IE C does not approve of 
the planned analysis of the association between DNA variation and drug response, or if there is a local law or regulation pro hibiting the same, data analysis will be limited to
CYPC29 .Leftover extracted DNA will be stored for FBR if the participant (or legally acceptable representative) provides documented informed consent for FBR.
08CG6Z
PRODUCT:   MK-8189  22
PROTOCOL/AMENDMENT NO.:   017 -04  
MK-8189 -017-04FINAL PROTOCOL 21-JUL-2022
2 INTRODUCTION
2.1 Study Rationale
MK-8189, a PDE10A inhibitor, is being developed for the treatment of neuropsychiatric 
symptoms in dementia . Prior to conducting a larger proof of concept study ,this study will 
explore the safety and tolerability of MK -8189 in the Alzheimer’s disease population with or 
without agitation- aggression and/ or psychosis .
2.[ADDRESS_111397] study is to evaluate safety and tolerability in a similar patient 
population (participants with or without agitation- aggression and/or psychosis associated 
with Alzheimer’s disease) prior to conducting a larger POC study.  C urrent treatment for 
neuropsychiatric symptoms associated with dementia often involve sthe off -label use of 
atypi[INVESTIGATOR_16709] (AAPs) . However, AAPs have a black box warning in the US with 
regards to the increased risk of death among elderly patients with dementia -related psychosis, 
which ultimately creates a therapeutic unmet need in elderly patients with dementia -related 
agitation and aggression [Marcinkowska, M., et al 2020] .Increased availability of D2 and D3 
receptors in the striatum as well as cortical dysfunction have been implicated in the 
pathophysiology of AAD [Kales, H. C., et al 2015] .  The PDE10A enzyme metabolically
inact ivates the ubiquitous second messengers, cAMP and cGMP [Bender, A. T. and Beavo, J. 
A. 2006] and is highly expressed inthetarget nucleus ofthecorticostriatal pathway, the
striatum and to a lesser extent the cortex and hippocampus [Seeger, T. F., et al 2003] . 
Preclinical pharmacology studies demonstrate that PDE10A inhibition increases
cAMP/cGMP signaling in the striatum which results in activation of the D2 pathway and 
potentiation of cortical striatal signaling leading to increased behavioral control [Grauer, S. 
M., et al 2009] [Schmidt, C. J., et al 2008] . 
PDE10A inhibitors have also been shown to decrease psychomotor activity, reverse deficits 
in pre -pulse inhibition, and inhibit conditioned avoidance responding in assays that are 
hypothesized to translate to efficacy on psychosis, agitation, and aggression [Smith, S. M., et 
al 2013] [Grauer, S. M., et al 2009] .In addition, PDE10A inhibitors have beneficial effects 
on preclinical measures of cognitive performance in nonhuman primates [Smith, S. M., et al 
2013] [Vardigan, J. D., et al 2016] .In the Phase 2a POC study , inan exploratory analysis, 
MK-8189 showed nominal improvement in the PANSS Marder Factor Hostility/Excitement 
Symptom Score and Disorganized Thought Symptom Score. Thus ,based on preclinical and 
clinical evidence, MK -[ADDRESS_111398]:   MK-8189  23
PROTOCOL/AMENDMENT NO.:   [ADDRESS_111399] one dose of MK- 8189; [ADDRESS_111400] been given to 48 healthy men, 22
with an IR formulation and 26 with a CR formulation. Ten healthy male and female 
participants received multiple doses titrated up to 12mgover 14days (P003 Part3)and12
healthy male andfemale participants received doses titrated up to 24 mg over 18 days (P007 
Panel A). Thirty- three male and female participants with schizophrenia were titrated up to 
doses of 16 mg over 14 days (P003), 25 participants with schizophrenia were titrated up to 24 
mg over 18 days (P007 Panel sB and C) and 17 participants with schizophrenia were titrated 
up to 48 mg over 15 days (P007 Panel D).Allmultiple -dose studies were conducted with a
CRformulation.
MK-[ADDRESS_111401] common
treatment -related adverse events [AEs] (≥5%) following treatment ofMK-8189 (n=146) 
across thecompleted 6Phase 1studies in healthy participants and participants with 
schizophrenia were headache (16.4%) ,somnolence (12.3%), decreased appetite (10.3%),
nausea (9.6%), fatigue (8.9%), dizziness (8.9%), vomiting (6.2%) ,diarrhea (6.2%), akathisia 
(6.2%), and anxiety (6.2%). Mos t AEs were mild to moderate in severity. There were no 
deaths and 2 SAEs. One healthy participant experienced an SAE of gastroenteritis in P003 
which was not considered treatment related . The other SAE of severe treatment -related 
psychosis occurred in a participant with schizophrenia following titration up to and 
administration of the 36 mg dose ( P007 ). The participant discontinued MK -[ADDRESS_111402] epi[INVESTIGATOR_100881], with three
events lasting one or more days. Only one participant discontinued due to an AE of dystonia.
In summary, eight participants (8.9%) had an AE of dystonia and 2 pa rticipants (2.2%) had
an AE of oromandibular dystonia. The intensities of the dystonia AEs were mild and
moderate with most reported as mild. Onset of dystonia occurred mostly during the
intervention titration period at the [ADDRESS_111403] events and up to six days. One participant discontinued study 
intervention due to dystonia. Two participants experienced 2 epi[INVESTIGATOR_100882]. One participant experienced both events during the 8 
mg dose level (mild, moderate), while another participant experienced one event during the 4 
mg (moderate) and one during the 8 mg (mild) dose level. The AEs of dystonia, except for
one incident, were consid ered related to study intervention by [CONTACT_473].
Individual studies aresummarized intheIB.
08CG6Z
PRODUCT:   MK-8189  24
PROTOCOL/AMENDMENT NO.:   017 -04  
MK-8189 -017-04FINAL PROTOCOL 21-JUL-2022
Summary of MK -8189 Pharmacokinetics
Following multiple doses of the controlled release formulation, MK- 8189 exposure increased 
approximately proportional ly with dose over the range of doses tested (2 to 48 mg) in all 
populations. Median Tmax of MK- 8189 as monotherapy ranged from 10 to 24 hours with a 
t1/[ADDRESS_111404] that the 
exposures at steady sta te for a given dose are generally comparable between healthy 
participants and participants with schizophrenia administered MK -8189 as monotherapy.
Preliminary results from the ongoing study P011 (described in 2.2.3) suggest that PK 
exposures in elderly par ticipants with and without schizophrenia are similar to one another 
and similar to those observed in adult participants < 60 years of age with schizophrenia. 
While there was significant overlap in the individual PK parameter values for elderly and 
non-elderly participants, in healthy elderly participants, on average, C24 values were 
approximately 50% higher than C24 values in non -elderly adults and elderly participants 
with schizophrenia. 
MK-8189 is a CYP3A substrate and in a DDI study (P006) the coadminis tration of extended 
release 240 -mg diltiazem, a moderate CYP3A inhibitor, increased MK -8189 AUC and Cmax 
by [CONTACT_3450] 2- fold and 1.3- fold, respectively .  In another ongoing DDI study (P015 , 
described in 2.2.3) the coadministration of itraconazole , a strong CYP3A inhibitor, increased 
MK-8189 AUC and Cmax by [CONTACT_3450] 1.2- fold and 1.14- fold, respectively, and were 
generally consistent with the results observed in the diltiazem study .  Collectively, these 
results confirm that MK -8189 is a CYP3A substrate.
2.2.3 Ongoing Clinical Studies
As of October 29, 2021, three Phase 1 trials and one Phase 2 trial are ongoing. All data
presented arepreliminary.
[IP_ADDRESS] Protocol 011
P011 is a Phase 1 multiple -dose randomized ( Panels A/B/C/D/E -3 active:1 placebo ; Panel 
F/G -5 active:1 placebo ), double -blind, placebo- controlled, multicenter, 2- part study. Part 1
(Panel A/B/C) is evaluating the safety and tolerability of different titration regimens or 
initiating MK -8189 treatment without titration in participants ≤60 years of age with 
schizophrenia. Part 2 is evaluating the multiple dose safety, tolerability ,and PK of MK- 8189 
inelderly participants with schizophrenia (Panel D and Panel E) and healthy elderly 
participants (Panel F and Panel G) between 61 and 80 years of ag e(inclusive) .  Panel E and 
Panel G will explore safety and tolerability at different titration regimens and will only be 
initiated after a safety and tolerability review from Panel D and Panel F, respectively .
In Part 1, Panel A, participants with schizophrenia initiated dosing with 16 mg of MK -
8189/placebo for 3 days and then were escalated to 24 mg/placebo for 4 days. In Panel B ,
participants with schizophrenia initiated dosing with 24 mg of MK-8189/placebo (no 
titration) for [ADDRESS_111405]:   MK-8189  25
PROTOCOL/AMENDMENT NO.:   [ADDRESS_111406] AEs were mild, and no AEs 
were severe in intensity. All AEs resolved. Of the 8 participants, one participant did not dose 
escalate to 24 mg /placebo due to moderate somnolence which lasted for [ADDRESS_111407] dose and lasted 2 da ys. The dystonia 
was treated with benztropi[INVESTIGATOR_100883]. The participant continued dosing with MK -
8189/placebo without recurrence of dystonia. Another participant reported mild transient 
dystonia which began 6.[ADDRESS_111408] dose and resolved in 22 hours. While 
experiencing dystonia the participant was treated with benztropi[INVESTIGATOR_050]. The participant continued 
to dose with MK -8189/placebo and escalated to 24 mg /placebo without a recurrence of 
dystonia. AEs reported (including those already discussed) considered related to study drug
included decreased appetite (n=2), dystonia (n=2) somnolence (n=2), nightmare (n=1),
worsening psychosis (n=1), andinsomnia (n=1).
In Panel B , enrollment and dosing are complete .Participants received MK -8189 24 
mg/placebo Days 1 -7. Eighteen participants were randomized and 14 completed treatment 
per protocol. Of the 4 participants that discontinued treatment, 3 withdrew consent and 1 
participant discontinued due to AEs of nausea and vomiting that w erenot con sidered related 
to treatment. This participant had a history of gastroesophageal reflux disease that was 
ongoing throughout the trial. The other participants withdrew consent. No AEs were 
considered severe and t he majority of AEs were mild. Except for an unrelated AE of 
ligament sprain, all AEs resolved. AEs considered related to treatment included somnolence 
(n=2), hypertonia (n=1), decreased appetite (n=1), musculoskeletal stiffness (n=1) and 
increased ALT (n=1). The participant with the AE of elevated ALT had an elevated 
screening value of 61 IU/L (normal range 7- 52 IU/L). The Day -1predose ALT value was 
also elevated (98 IU/L) and continued to increase on Day 7 (116 IU/L) and Day 9 (133 IU/L).
At the poststudy the ALT was still elevated but below the predose value (71 IU/L). ALP
(normal range 34 -104 IU/L) followed a similar pattern with elevations atscreening (130
IU/L), Day -1predose (136 IU/L), Day 7(143 IU/L), Day 9(134 IU/L) and at the poststudy 
visit (124 IU/L). While AST was within the normal range (13 -39IU/L) at screening (26 
IU/L) and Day - 1 predose (37 IU/L), values were elevated above the normal range on Day 7 
(44 IU/L) and Day 9 (51 IU/L). At the post study visit, AST was within the normal range (26 
IU/L). Bilirubin was normal throughout the study. Preliminary data suggest initiation of MK -
8189 at a 16 mg or 24 mg dose was generally well tolerated. NoAEs of akathisia ordystonia
were reported. 
Panel C wasnot conducted perprotocol since theregimens inPanel A andBwere generally
well tolerated.
Treatment is ongoing in Part 2. Panel D is currently enrolling elderly participants with
schizophrenia. Participants will receive MK -8189 8 mg/placebo Days 1 -3, MK -8189 16
mg/placebo Days 4 -6and MK -8189 24 mg/placebo Days [ADDRESS_111409] AEs were mild or moderate 
and 1 AE was severe (described below). All AEs reported to date have resolved except an 
08CG6Z
PRODUCT:   MK-8189  26
PROTOCOL/AMENDMENT NO.:   [ADDRESS_111410] 
discontinued the trial: 
One participant withdrew consent, and no treatment- related AEs were reported for this 
participant.
One participant reported anAE of severe somnolence which began following the 8 
mg/placebo dose and resolved on Day 3 following administration of the 8 mg/placebo dose.
OnDay 3following treatment with 8mg/placebo, theparticipant hadanAEof moderate 
dystonia which resolved in 2 days with a single -dose of cyclobenzaprine. This participant 
reported moderate akathisia following treatment with 8 mg/placebo which continued for3
weeks. This participant haddrug interrupted andsubsequently discontinued following the
second 16mg/placebo dose duetomoderate treatment -related AEs ofdermatitis and
conjunctivitis. Noother treatment -related AEs were reported.
One participant experienced dystonia of the throat after the Day 3 16 mg/placebo dose which 
was treated with benztropi[INVESTIGATOR_100884]’s difficulty to swallow.  The 
participant continued to have tightness of throat muscles which the investigator considered to 
be mild dystonia which persisted for [ADDRESS_111411] dose of 24 mg/placebo.  This panel is still actively 
dosing and the following treatment related AEs have been reported to date (includes AEs 
which have been reported above) ; dystonia (n=2), internal restlessness (n=2), somnolence 
(n=1), akathisia (n=1), conjunctivitis (n=1), dermatitis (n=1), dizziness (n=1), dysge usia 
(n=1), ear discomfort (n=1) , oral hypoesthesia (n=1) and involuntary movement of lower 
extremities (n=1)
Panel F is clinically complete and enrolled [ADDRESS_111412] been reported. Except for hyponatremia (discussed below) , 
all other reported AEs resolved. One subject discontinued the trial due to treatment related 
AEs of nausea , vomiting , dyspepsia, and h yponatremia . This participant also reported 
diarrhea prior to the onset of nausea and vomiting. The hyponatremia was resolving at the 
time of participant discharge. One participant was down- titrated from 24 mg/placebo to 16 
mg/placebo following the onset of moderate EPS. The EPS had a duration of approximately 
2 weeks and was managed intermittently with benztropi[INVESTIGATOR_050] . This participant completed 
treatment and the study. The treatment -related AEs reported (including those discussed
above) were decreased appetite (n=1), dizziness (n=1), nausea (n=1), vomiting (n=1), 
dyspepsia (n=1), hyponatremia (n=1), somnolence (n=1), involuntary muscle contractions 
(n=1), tremor (n=1), extrapyramidal disorder (n=1) and salivary hypersecretion (n=1).
08CG6Z
PRODUCT:   MK-8189  27
PROTOCOL/AMENDMENT NO.:   017 -04  
MK-8189 -017-04FINAL PROTOCOL 21-JUL-2022
Panel G completed dosing in healthy elderly participants. Participants received MK -8189 16
mg/placebo Days 1 -3, MK -8189 24 mg/placebo Days 4- 10.Fifteen participant swere
enrolled. N o deaths or SAEs were reported. Most AEs were mild and3AEs were severe ( 2 
participants with severe somnolence and 1 partici pant with severe hypnagogic hallucination) 
and are described below. All AEs resolved. Three subjects discontinued due to treatment 
related AEs. The evening of Day 7, f ollowing 2 days of dosing with MK -8189 24 
mg/placebo, through the early morning hours of Day 8, one participant reported mild 
akathisia (~20 hour) ,moderate tactile hallucinations (15 min), mild palpi[INVESTIGATOR_814] (2 min) and 
bilateral hand hyperhidrosis (5 hour) and in the predawn hours the participant reported severe
hypnagogic hallucinations (5 min) .The participant did not report these AEs until the morning 
of Day 8, at which time the dose was held and the participant received treatment with 
benztropi[INVESTIGATOR_100885]. Later in the afternoon of Day 8 ,the participant had a 
recurrence of akathisia, bilateral hand hyperhidrosis, tactile hallucinations andreported sinus 
tachycardia, all which resolved with the treatment with benztropi[INVESTIGATOR_050] . On Day 8 the participant 
discontinued treatment due to these AEs. This participant also had a brief epi[INVESTIGATOR_1865] (~30 min) 
of mild oral mandibular dystonia on Day 1 (16 mg/placebo) that resolved spon taneously.  
Another subject discontinued due to an AE of mild akathisia (~24 hour) following treat ment 
with 16 mg/placebo dose on Day [ADDRESS_111413] discontinued after 2 days of dosing at the 24 mg/placebo dose (Day 5) due to 
moderate oromandibular dystonia (~6 hours ) and moderate anxiety (<24 hours duration); 
both AEs responded to treatment .
In addition to the participant with the brief but severe hypnagogic hallucination, [ADDRESS_111414] dose of study intervention (16 mg/placebo) and resolved in 
≤ 10 hours. All treatment related AEs reported (including those discussed above) were
somnolence (n=4), akathisia (n=3), oromandibular dystonia (n= 2), myalgia (n=2), tremor 
(n=2), headac he (n=2), involuntary muscle contractions (n=2), tactile hallucination (n=1), 
palpi[INVESTIGATOR_814] (n=1), bilateral hand hyperhidrosis (n=1), hypnagogic hallucination (n=1), sinus 
tachycardia (n=1), restlessness (n=1), dyspepsia (n=1), vomiting (n=1), paresthesia (n=1), 
insomnia (n=1) , apathy (n=1) dysphonia (n=1), salivary hypersecretion (n=1), anxiety (n=1), 
bilateral hands rapid alternating movements (n=1) and smell sensitivity (n=1). 
[IP_ADDRESS] Protocol [ADDRESS_111415] been reported. The following treatment related AEs (duration) have been 
reported by 3 participants: One participant had mild AEs of a hot flush (40 min), vomiting (1 
epi[INVESTIGATOR_1865]) and leg cramps (10 min). One participant had a mild AE of dizziness (<1 day)
which resulted in a fall .One par ticipant had mild AEs of headache (<1 day),anxiety (30 min)
andaffect lability (30min).
08CG6Z
PRODUCT:   MK-8189  28
PROTOCOL/AMENDMENT NO.:   017 -04  
MK-8189 -017-04FINAL PROTOCOL 21-JUL-2022
[IP_ADDRESS] Protocol [ADDRESS_111416] one AE considered related to MK -
8189 and/or itraconazole (duration). One participant discontinued duetoAEofmild rash (2
days) toitraconazole. InPeriod 1onDay 1, one participant reported mild AEs of somnolence 
(1 day) and dizziness (8.5 h ours)considered related to MK -8189. In Period 2 on Day 4, this 
same participant reported mild restlessness (20 hours )and an ECI of dystonia (12 h ours) of 
moderate severity considered related to MK -8189 and itracona zole.The dystonia resolved 
without treatment. Following a blood draw, t wo other AEs, mild presyncopal event (5 min) 
and mild faint sensation (12 min) ,were also reported by [CONTACT_100905]. One other participant reported an AE of mild 
dystonia (~ 2 days) which began in Period 2 on Day 5. The dystonia resolved without 
treatment and was considered related to MK -8189 and itraconazole . One participant had mild 
AEs of somnolence (2 days) and diarrhea (9 days). The somnolence began in Period 1 on 
Day 1 and was considered related to MK-8189, and the diarrhea began in Period 2 prior to 
co-dosing of MK- 8189 and was considere d related to itraconazole. Three other participants 
reported mild diarrhea (5 hours , 3days and 6 days) which began inPeriod 2prior toMK-
8189 administration.
[IP_ADDRESS] Protocol 008
P008 isanongoing Phase 2Brandomized, double -blind, placebo -andactive controll edtrial
of the efficacy and safety of MK- 8189 in adult participants 18 to 50 years of age who are
experiencing anacute epi[INVESTIGATOR_100886] -V™ criteria.
Atotal of 576 participants from approximately 80 sites across the[LOCATION_003], Europe andAsia will  
be recruited into this trial. Treatment duration will be for a period of 12 weeks and includes a
6-week acute treatment period followed by a 6 -week extension period. Eligible participants
will be randomized to receive one of five tre atment sequences with target doses of MK -8189
(8 mg, 16 mg
,and 24 mg QD), risperidone (6 mg QD), or placebo. Placebo completers at 6
weeks will be allocated to receive MK -8189 24 mg for the remainder of the trial. This trial is
being conducted inahospit al/acute care setting followed by[CONTACT_100906]. 
Recruitment wasinitiated in December 2020.
2.3 Benefit/Risk Asse ssment
Participants in clinical studies will not receive direct benefit from treatment during 
participation as clinical studies are designed to provide information about the safety and 
properties of an investigational medicine. 
08CG6Z
PRODUCT:   MK-8189  29
PROTOCOL/AMENDMENT NO.:   017 -04  
MK-8189 -017-04FINAL PROTOCOL 21-JUL-2022
Additional details regarding speci fic benefits and risks for participants participating in this 
clinical study may be found in the accompanying IB and informed consent documents.
3 HYPOTHESE S, OBJECTIVES ,AND ENDPOINTS
There are no hypothes es for this study.  
In male or female participants with Alzheimer’s Disease with or without symptoms of
agitation-aggression and/or psychosis .
Objectives Endpoints
Primary
•To evaluate the safety and tolerability of 
multiple ascending doses of MK -8189 in 
participants with Alzheimer’s Disease 
with or without symptoms of agitation-
aggression and/or psychosis•Adverse events
•Adverse experiences leading to 
discontinuation of study intervention
Secondary
•Not applicable
Tertiary/Exploratory
•To evaluate the trough exposures of 
MK-8189•C24hr
•To investigate the relationship between 
CYP2C9 genetic polymorphs and the 
PK of MK -8189. Genetic variation in 
CYP2C9 may be analyzed for 
association with any laboratory or 
clinical data collected in this study•Germline genetic variation in CYP2C9 
and associat ion to clinical data collected 
in this study
•To explore the relationship between 
genetic variation and response to the 
treatment administered, and mechanisms 
of disease. Variation across the human 
genome may be analyzed for association 
with clinical data collected in this study•Germline genetic variation and 
association to clinical data collected in 
this study
•To explore changes in cognitive 
functioning, neuropsychiatric status and 
extrapyramidal symptomatology•MMSE -[ADDRESS_111417]:   MK-8189  30
PROTOCOL/AMENDMENT NO.:   017 -04  
MK-8189 -017-04FINAL PROTOCOL 21-JUL-2022
4 S TUDY DESIG N
4.1 Overall Design
This is a randomized, placebo -controlled, parallel- group, multisite, double -blind study of 
MK-8189 in participants with Alzheimer’s Disease with and without neuropsychiatric 
symptoms.  To most closely simulate the patient population for th e indication evaluated, it is 
preferred that participants included in this study have symptoms of agitation-aggression or 
psychosis (defined as a severity of score ≥1 and frequency score of ≥ 2 on the NPI [INVESTIGATOR_100887] -
Aggression and/or Delusions and/or Halluci nations domains). 
Up to a pproximately [ADDRESS_111418] 16 participants 
complete the study. Note: Greater than [ADDRESS_111419] a trial partner/caregiver as descr ibed in 
the inclusion/exclusion criteria.
The first 8 participants will be randomized to receive MK -8189 8 mg/placebo QD Days 1 -3, 
16mg/placebo QD Days 4 -28(Titration 1) . Participants may be down- titrated by [CONTACT_100907].  Changes in the dosage regimen will be communicated to the Sponsor and 
the Sponsor will document changes in a Protocol Clarification Letter. After approximately [ADDRESS_111420] completed approximately 3 weeks of dosing, AE data will be reviewed to 
determine whether to continue to enroll participants at the Titration 1 regimen or whether 
participants should r eceive a nalternate dosing regimen ( e.g., MK-8189 8 mg/placebo QD 
Days 1 -3, 16 mg/placebo QD Days 4 -6, 24 mg/placebo Days 7 -28(Titration 2) OR MK -8189 
4 mg /placebo QD Days 1- 3, 8 mg/placebo Days 4- 6, 16 mg Days 7 -9, 24 mg Days 10- 28
(Titration 3) ).Prior to initiation of an alternate regimen that includes escalation to a dose 
above 16 mg, the PK data from the initial cohort of participants will be required to be 
reviewed.  The decision wil lbe made jointly between the investigators and the Sponsor and 
any change to the dosing regimen will be documented in a Protocol Clarification Letter. See 
section 6.6 for allowed dose modifications.
As MK -8189 is not a treatment for Alzheimer’s disease, participants may remain on their 
current Alzheimer’s treatment as o utlined in S ection 6.[ADDRESS_111421]:   MK-8189  31
PROTOCOL/AMENDMENT NO.:   017 -04  
MK-8189 -017-04FINAL PROTOCOL 21-JUL-2022
If the investigator considers it appropriate for an individual participant to be domiciled (i.e. ,
exacerbation of dementia or behavioral symptoms not expected), the participant may be 
domiciled through the titration period or for the entire intervention period (Day 1- 28)(refer 
to Section 8.1.12).  Any other duration of domiciling should be discussed with the S ponsor , 
except when considered necessary for participant safety .
Because this is a Phase [ADDRESS_111422] of a larger POC study, this smaller study (n=2 8, randomized such that 21 
are on MK -8189 and 7 on placebo ) will be conducted as an initial assessment of safety and 
tolerability in a similar patient population. 
This will be a randomized, placebo -controlled study to ensure an objective assessment of 
safety and tolerability. An outpatient trial is preferred as changing the environment in this 
patient population may adversely affect cognitive status. However, if deemed appropriate by 
[CONTACT_093], a participant may be domiciled as described in Section 8.1.[ADDRESS_111423] MK -8189 is generally well 
tolerate d,supporting outpatient dosing (refer to Section 2.2) . However , as the tolerability 
may differ in a population with AD, the study will first enroll only 8 participants to ensure 
tolerability of the selected treatment regimen. If tolerability issues are fo und, a more 
conservative regimen will be administered to the remaining participants. At any time during 
treatment, the investigator may choose to down -dose a participant. The assessment of MK-
8189 safety and tolerability from this trial , in which participa nts with AD with or without 
agitation- aggression and/or psychosis will receive study treatment for one month, will be 
used to determine if longer term safety and efficacy trials can be supported. Daily telephone 
calls by [CONTACT_100908], weekly s afety evaluations and the requirement for 
participants to have a trial partner /caregiver willhelp ensure participant safety and 
compliance with study intervention administration and protocol requirements throughout the 
study.
As effi cacy will not be assessed in this study, participants without or with neuropsychiatric 
symptoms (agitation-aggression or psychosis )will be permitted in the study. Those who are 
currently taking antipsychotics to control neuropsychiatric symptoms may be en rolled if it is 
clinically appropriate to have participants wash off their medication ( e.g., participant is not 
tolerating current treatment or is not likely receiving benefit from the treatment).  This will 
08CG6Z
PRODUCT:   MK-8189  32
PROTOCOL/AMENDMENT NO.:   017 -04  
MK-8189 -017-04FINAL PROTOCOL 21-JUL-2022
ensure the safety and tolerability profile of MK- 8189 is understood without confounding 
antipsychotic treatment.  However, if during the study, neuropsychiatric symptoms worsen, 
rescue therapy specified may be administered.
4.2.1 Rationale for Endpoints
[IP_ADDRESS] Efficacy Endpoints
Not Applicable
[IP_ADDRESS] Safety Endpoints
Safet y and tolerability will be assessed throughout the study by [CONTACT_100909], 12 -
lead ECGs, VS, and laboratory safety tests. 
The C -SSRS will be administered to monitor mood and suicidal ideation and behavior in all 
trial participants (see Section 4.2.3) .
Exploratory Safety Endpoints
As EPS are associated with antipsychotics and have been observed in the MK -8189 clinical 
program, the BARS, AIMS and SAS will be used to evaluate EPS throughout the study per 
the SoA. The BARS, comprised of objective and subjective items, as well as a global rating , 
assesses drug -induced akathisia. The global rating score ranges from 0 to 5, where 0 
represents no eviden ce for akathisia, a score of 3 is moderate akathisia and a score of 5 is 
severe akathisia. The AIMS includes 12 items and uses a 5- point scale to assess abnormal 
movement in 3 areas (orofacial, extremities, trunk). The SAS is comprised of 10 items and 
uses a 5-point scale to measure symptoms of parkinsonism or parkinsonian side effects 
(including rigidity, tremor, bradykinesia/ akinesia, and salivation).
The Mini -Mental State Exam, Edition 2, Standard Form (MMSE -2) assesses orientation, 
attention, memory, la nguage, and visual- spatial skills and has a score range of 0- 30, where 
higher scores reflect better performance .A score between 21 to 26 typi[INVESTIGATOR_100888] a 
participant is experiencing mild cognitive dysfunction impairment, while scores in the rang e 
of 10- 20 are indicative of participants with more moderate cognitive impairment. The 
MMSE -2 administered at screening will be used forinclusion to ensure that enrolled 
participants fall into the cognitive impairment categories of mild to moderate severity. In 
addition, the MMSE -2 will be repeated as specified in the SoA to explore any changes in 
cognitive impairment. 
The Neuropsychiatric Inventory ( NPI)assesses behavioral and psychological domains and 
symptoms, including delusions, hallu cinations, agitation or aggression, dysphoria or 
depression, anxiety, euphoria or elation, apathy or indifference, disinhibition, irritability or 
lability, aberrant motor behavior , sleep/nighttime behavior and appetite/eating disturbances .  
The NPI [INVESTIGATOR_41509] s both symptom frequency (scored 1- 4) and severity ratings (scored 1 -3), as 
well as trial partner /caregiver distress ratings .
08CG6Z
PRODUCT:   MK-8189  33
PROTOCOL/AMENDMENT NO.:   017 -04  
MK-8189 -017-04FINAL PROTOCOL 21-JUL-2022
[IP_ADDRESS] Pharmacokinetic Endpoints
An exploratory objective of this study is to characterize the trough exposures of MK -8189. 
Therefore, individual plasma concentration and actual sample collection times of MK -8189 
will be used to derive the PK parameter value forC24hr.
[IP_ADDRESS] Planned Exploratory Biomarker Research
[IP_ADDRESS].[ADDRESS_111424] a participant’s response to therapy, susceptibility to, severity, 
and progression of disease. Variable response to therapy may be due to genetic determinants 
that impact drug ADME ; mechanism of action of the drug; disease etiology; and/or 
molecular subtype of the disease being treated. Therefore, where local regulations and 
IRB/IEC allow, a sample will be collected for DNA analysis from consenting participants.
DNA samples may be used for research related to the study intervention(s), the disease under 
study, or related diseases. They may also be used to develop tests/assays including diagnostic 
tests related to the disease under study, related diseases, and study intervention(s). Genetic 
research may consist of the analysis of 1 or more candidate genes , the analysis of genetic 
markers throughout the genome , or analysis of the entire genome. Analysis may be 
conducted if it is hypothesized that this may help further understand the clinica l data.
The samples may be analyzed as part of a multistudy assessment of genetic factors involved 
in the response to understand study disease or related conditions.
In addition to studying variation across the human genome, polymorphs of CYP2C9 will
speci fically be investigated for association with the PK and PD of MK -8189 since MK -8189
is partially metabolized by [CONTACT_097]2C9. Genetic variation in CYP2C9 may be analyzed for
association with any laboratory or clinical data collected in this study.
[IP_ADDRESS] Future Biomedi cal Research
The Sponsor will conduct FBR on specimens for which consent was provided during this 
study. This research may include genetic analyses (DNA), gene expression profiling (RNA), 
proteomics, metabolomics (serum, plasma), and/or the measurement of other analytes, 
depending on whi ch specimens are consented for FBR .
Such research is for biomarker testing to address emergent questions not described elsewhere 
in the protocol and will only be conducted on specimens from appropriately consented 
participan ts. The objective of coll ecting/retaining specimens for FBR is to explore and 
identify biomarkers that inform the scientific understanding of diseases and/or their 
therapeutic treatments. The overarching goal is to use such information to develop safer, 
more effective drugs/vaccines, and/or to ensure that participants receive the correct dose of 
the correct drug/vaccine at the cor rect time. The details of FBR r esearch are presented in
Appendix 6.
08CG6Z
PRODUCT:   MK-8189  34
PROTOCOL/AMENDMENT NO.:   017 -04  
MK-8189 -017-04FINAL PROTOCOL 21-JUL-2022
4.2.2 Rationale for the Use of Comparator/Placebo
As the safety and tolerability profile is under continued evaluation , aplacebo -control willbe
included inthistrialtoensure objective assessment ofAEs.
4.2.3 Rationale for Suicidal Ideation and Behavior Monitoring
Prospective assessment of suicidal ideation an d behavior will be performed in this study 
using the C -SSRS. This assessment is being conducted in compliance with the 2012 FDA 
guidance requiring prospective assessment in cl inical studies conducted under IND 
applications and studies that ar e intended for submission in a NDA to the Neurology or 
Psychiatry Divisions of the FDA or BLA , as well as assessment in studies that fall within the 
guidance for other reasons ( e.g., CNS active/penetrant compounds, and known mechanisms 
or indications for which suicidal ideation/behavior has been previously identified as a 
potential concern).
4.3 Justification for Dose
Currently the efficacious dose of MK -8189 is unknown, however, based on data from in vivo 
preclinical assays ( see Section 2. 1andtheIB), enzyme occupancy of 30% is expected to be 
required for efficacy in neuropsychiatric symptoms associated with dementia. A dose of 8 mg 
isexpected to result in a mean C24 (90% confidence interval ) enzyme oc cupancy of
approximately 40% ( 34, 47). Proof of concept has be en established for 12 mg of MK -8189 in 
schizophrenia patients (P005), however, doses up to and including 24 mg are being evaluated 
in a Phase 2b study (P008) to understand if greater efficacy is observed with higher doses. 
Recent literature suggests that f or antipsychotics to be effective in the treatment of behavioral 
symptoms associated with dementia, doses may need to be similar to those used for the 
treatment of schizophrenia [Grossberg, G. T., et al 2020] . Preliminary PK data from P011 
suggest the median C24 value in healthy elderly following multiple doses of MK -8189 16 mg 
will be similar to that observed following multiple 24 mg doses of MK- 8189 in non -elderly 
adults with schizophrenia.  Therefore, the initial titration regimen in the current study will 
escalate MK -8189 doses up to 16 mg. If multiple doses of MK-8189 16 mg is generally well 
tolerated in the initial cohort of ~8 participants and, based on a PK analysis of the se
participants, MK -8189 exposure is less than anticipated and thus closer to exposures 
observed in younger (< 60 years of age) adult participants, an alternate titration regimen 
escalati ngto 24 mg of MK -8189 (Titration Regimen 2) may be expl ored.  
As this is a Phase 1 assessment of MK -8189 inhumans, and the PK, pharmacodynamic and 
safety profiles of the compound are still being evaluated, modifications to the dose or dosing 
regimen may be required to achieve the scientific goals of the study objectives and/or to 
ensure appropriate safety monitoring of the study participants. Details of allowed 
modifications are provided in Section 8.10.7.
4.3.[ADDRESS_111425] 8 p articipants will receive the following treatment regim en: MK -8189 8mg/placebo 
Days 1 -3and16 mg/placebo Days [ADDRESS_111426]:   MK-8189  35
PROTOCOL/AMENDMENT NO.:   017 -04  
MK-8189 -017-04FINAL PROTOCOL 21-JUL-2022
8189 has been found to be generally well -tolerated in healthy elderly participants and young 
participants.  In young participants with schizophrenia ,a starting dose as high as 24 mg has 
been evaluated and found to be well tolerated (see Section 2.2).  The remaining participants 
will receive the same dose treatment regimen or an alternate treatment regimen.  The starting 
dose for the selected regimen will not exceed 8 mg of MK -8189.
4.3.2 Maximum Dose/Exposure for This Study
Participants may be escalated to a maximum MK -8189 dose of 24 mg/placebo.  A daily dose 
of MK -8189 24 mg has been found to be generally well tolerated in hea lthy young (P007) 
and elderly participants (P011) and dose sof MK -[ADDRESS_111427] be engenerally well 
tolerated in participants with schizophrenia (P007). 
Based on a population PK model, the steady -state Cmax and AUC0- 24hr at the 24- mg dose 
is predicted to be 0.975 µ M and 19 µM.hr. Based on data from the chronic toxicology 
studies, the exposure multiple at the 24 mg dose for AUC0 -24hr would be ~7- fold based on 
the 6- month rat study and ~9 -fold based on the 9 -month monkey study. Brief summaries of 
the chronic toxicology studies supporting dose escalation are provided below:
In the 6 -month rat study, doses of 0, 25, 100 and 750 mg/kg/day were evaluated. Two high -
dose (750 mg/kg/day) female rats were found dead (Week 13 and Week 24) with acute 
tubular necrosis (with and without tubular mineralization). Therefore, the 100 mg/kg/ day 
dose was considered the no observed adverse effect level (NOAEL) for this study (AUC0 -
24hr = 130 μM ∙hr), providing an exposure margin of ~7 -fold over the predicted exposure of 
19 μM ∙hr at the 24 mg dose.
In the 9 -month monkey study, doses of 0, 30/10/3, 150 or 600/300 mg/kg/day of MK- 8189 
were administered. Renal tubular degeneration was observed in the high -dose group (600/300 
mg/kg/day). The NOAEL for target organ toxicity is 150 mg/kg/day (AUC0- 24hr = 170 
μM∙hr), providing ~9 -fold over the predicted exposure of 19 μM ∙hr at the 24- mg dose. 
Therefore, clinical and preclinical data support dose escalation to [ADDRESS_111428] participant (or their legally acceptable representat ive) 
provides documented informed consent . The overall study ends when the last participant 
completes the last study -related contact , withdraws consent , or is lost to follow -up (ie, the 
participant is unable to be contact[CONTACT_19379]) .
08CG6Z
PRODUCT:   MK-8189  36
PROTOCOL/AMENDMENT NO.:   017 -04  
MK-8189 -017-04FINAL PROTOCOL 21-JUL-2022
Astudy may be paused during review of newly available preclinical/ clinical safety, PK , 
pharmacodynamic, efficacy, or biologic data or other items of interest, prior to a final 
decision on continuation or termination of the study. It may be necessary to keep the study 
open for gathering/reviewing of additional supportive data to optimally complete the 
objective(s) of the study. If necessary, the appropriate amendment(s) to the protocol and/or 
appropriate communication(s) will be generated. Ifthe decision has been made to end the 
study following this review period, the study end will be defined as the date of the Sponsor 
decision, and this end of study date supersedes the definitions outlined above . The 
Competent Authority(ies) and IRB(s)/IEC( s) will be apprised of the maximum duration of 
the study beyond the last participant out and the justifica tion for keepi[INVESTIGATOR_88635].
4.4.[ADDRESS_111429] for Clinical Trials (Section 10.1.1), our studies include 
people of varying age, race, ethnicity, and sex. The collection and use of these demographic 
data is to follow all local laws and guidelines in keepi[INVESTIGATOR_100889], its related factors, and the IMP 
under investigation. Prospective approval of protocol deviations to recruitment and 
enrollment criteria, also known as protocol waiv ers or exemptions, is not permitted.
This study will enroll male/female participants between the ages of 65 and 85 years 
(inclusive), with diagnosis of Alzheimer disease for at least [ADDRESS_111430] symptoms of agitation- aggression and/or psychosis (defined as a 
severity of score ≥1 and frequency score of ≥2 on the NPI [INVESTIGATOR_100887] -Aggression and/or 
Delusions and/or Hallucinations domains) for at least 4 weeks prior to Screening.
5.1 Inclusion Criteria
A participant will be e ligible for inclusion in the study if the participant:
Type of Participant and Disease Characteristics
1.Has a documented diagnosis of probable Alzheimer disease based on National Institute 
on Aging- Alzheimer Association criteria for AD, with a history of cognitive and 
functional decline with gradual onset and slow progression for at least 1 year before 
screening, that is either corroborated by [CONTACT_100910]. Note: PIs sh ould e nsure that non -neurological medical 
comorbidities, including treatable causes of dementia, have been ruled out at the time of 
diagnosis, including, but not limited to, hypothyroidism, B12, and folate deficiency as 
well as increased levels of homocyst eine.
2.Has an MMSE -2score between [ADDRESS_111431]:   MK-8189  37
PROTOCOL/AMENDMENT NO.:   017 -04  
MK-8189 -017-04FINAL PROTOCOL 21-JUL-2022
3.Lives in the community setting with a reliable trial partner/ caregiver or lives alone in an 
assisted living facility, with supervision and has a reliable trial partner/ caregiver .
4.Hasa reliable and competent trial partner/caregiver who must have a close relationship 
with the participant and is knowledgeable of the participant’s condition and progress and 
able to read, understand and speak the designated language at the study site. The
trialpartner /caregiver should understand the nature of the trial and adhere to 
trialrequirements (e.g., dos ing, visit schedules, and evaluations). The trial 
partner /caregiver must:
be willing to sign informed consent,
have face to face contact [CONTACT_100911] a week for a minimum of 8 waking 
hours a week (or more in accordance with local requirements), 
be willing to accompany the participant to all trial visits , as required per protocol 
(and arrange for an alternati ve transportation means when, on occasion, the trial 
partner /caregiver may not be available) and 
bewilling to monitor compliance of study intervention administration and record 
study intervention administration . 
5.Canread at the 6th grade level/equivalen t as determined by [CONTACT_093] .
6.Has an academic and/or employment history sufficient to exclude intellectual disability 
and is able, in the opi[INVESTIGATOR_871], to fully participate in the study (e.g., speak, 
read, hear, understand trial staff language )and be able to comply with protocol
assessments .
7.Is ingenerally good physical health based on medical history, physical examination, VS 
measurements, and ECGs performed before randomization. Participants with chronic 
medical conditions such as hypothyroidism, diabetes, high BP, chronic respi[INVESTIGATOR_100890] [ADDRESS_111432] mean 
systolic blood pressure of ≤150 mmHg and mean diastolic blood pressure of ≤95 mmHg 
at screening. In addition, screening orthostatic vital sign changes should be 
asymptomatic with a standing systolic blo od pressure of ≥[ADDRESS_111433]:   MK-8189  38
PROTOCOL/AMENDMENT NO.:   017 -04  
MK-8189 -017-04FINAL PROTOCOL 21-JUL-2022
9.Participants receiving treatment with a cholinesterase inhibitor or other treatment for AD
(i.e. memantine and aducanumab) , must have been on a stable regimen for [ADDRESS_111434] be discontinued 2 weeks or 5 half -lives (whichever 
was longer) prior to Baseline. Investigators should not withdraw a prohibited medication 
for the purpose of enrolling them into the study unless discontinuation of the medication 
was deemed to be clinically appropriate (e.g., symptoms are not well -controlled, or the 
subject can’t tolerate the current medication).
11.Has aBMI  > 18and ≤ 35 kg/m 2,inclusive. SeeSection 8.3.[ADDRESS_111435] whole number. BMI = weight (kg)/height (m)2.
Demographics
12.Ismale or female , 65years to 85years of age ,inclusive, at the time of signing the 
informed consent.
13.A female participant is eligible to participate if she is not pregnant or breastfeeding, and 
at least one of the following conditions applies: 
•Not a WOCBP
OR
•A WOCBP and:
-Uses an acceptable contraceptive method, or be abstinent from heterosexual 
intercour se as their preferred and usual lifestyle (abstinent on a long -term and 
persistent basis), as described in Appendix [ADDRESS_111436] dose of study intervention. The investigator should 
evaluate the po tential for contraceptive method failure (ie, noncompliance, recently 
initiated) in relationship to the first dose of study intervention. Contraceptive use by 
[CONTACT_93300] e participating in clinical studies
-Has a negative highly sensitive pregnancy test (serum or urine as required by [CONTACT_13125]) within [ADDRESS_111437] dose of study intervention. (If a urine 
test cannot be confirmed as negative [ eg, an ambi guous result ], a serum pregnancy 
test is required. In such cases, the participant must be excluded from participation if 
the serum pregnancy result is positive.) Additional requirements for pregnancy testing 
during and after study intervention are in Secti on 8. 3.5.
-Medical history, menstrual history, and recent sexual activity has been reviewed by 
[CONTACT_93301] a woman with an early undetected 
pregnancy.
08CG6Z
PRODUCT:   MK-8189  39
PROTOCOL/AMENDMENT NO.:   017 -04  
MK-8189 -017-04FINAL PROTOCOL 21-JUL-2022
Informed Consent
14.The participant (or legally acceptable representative) has provide ddocumented informed 
consent/assent for the study. The participant may also provide consent/assent for FBR. 
However, the participant may participate in the study without participating in FBR.
Additional Categories
15.Willing to comply with the study restrictions (see Se ction 5.3for a complete summary of 
study restrictions).
5.[ADDRESS_111438] be excluded from the study if the participant:
Medical Conditions
1.Hasagitation/aggression or psychosis that is attributable to concomitant medications, 
environmental conditions, substance abuse, or an active medical or psychiatric condition .
2.Has a MHIS Score > 4 at Screening ( i.e., evidence of vascular dementia ).
3.Has a known history of stroke or evidence from prior MRI scan (if available) that is 
clinically imp ortant in the investigator's opi[INVESTIGATOR_1649] .
4.Has evidence of a clinically relevant neurological disorder other than the disease being 
studied ( i.e., probable AD) at Screening, including but not limited to: vascular dementia, 
parkinsonism, frontotemporal dementia, Huntington's disease, amyotrophic lateral 
sclerosis, multiple sclerosis, progressive supranuclear palsy, neurosyphilis, dementia with 
Lewy bodies, posterior cortical atrophy, logopenic primary progressive aphasia, other 
types of dementia, intellectual disability , hypoxic cerebral damage, cognitive impairment 
due to other disorders, or head trauma with loss of consciousness that led to persist ent 
cognitive deficits.
5.Has a history of seizures or epi[INVESTIGATOR_100891] 5 years before Screening.
6.Has evidence of a clinically relevant or unstable psychiatric disorder, based on DSM -5 
criteria, including schizophrenia , schizophrenia spectrum or other psychotic disorder, 
bipolar disorder, major depress ive disorder , or delirium. Note: Major depress ive disorder
in remission is not exclusionary and m ild, stable ,treated depression is not exclusionary.  
7.Is at imminent risk of self -harm, based on clinical  interview or on the C- SSRS, or of harm 
to others in the opi[INVESTIGATOR_871]. Participants must be excluded if they report 
suicidal ideation with intent,  with or without a plan ( i.e., suicidal ideation Item 4 or 5 on 
the C -SSRS) in the past [ADDRESS_111439] 6 months.
8.Has a history of alcoholism or drug dependency/abuse within the last [ADDRESS_111440]:   MK-8189  40
PROTOCOL/AMENDMENT NO.:   017 -04  
MK-8189 -017-04FINAL PROTOCOL 21-JUL-2022
9.Has a history of cancer (malignancy).
Exceptions: (1) A dequately treated nonmelanomatous skin carcinoma or carcinoma in 
situ of the cervix or ; (2) Other malignancies that have been successfully treated with 
appropriate follow up and therefore unlikely to recur for the duration of the study, in the 
opi[INVESTIGATOR_100892] ( e.g., mali gnancies that 
have been successfully treated ≥10years prior to the prestudy [ screening ]visit).
10.Has a family history of prolonged QTc syndrome.
11.Has an estimated eGFR ≤50mL/min/1.[ADDRESS_111441] Equation :
eGFR (mL/min/1.73 m2) = 
175 x (serum creat inine )-1.154x (age)-0.203x (0.742 [if female]) x (1.212 [if black or 
African American])
At the discretion of the investigator a measured CrCl , as determined by a 24-hour urine 
collection, may be used in place of, or in conjunction with, the e stimate of the eGFR.
Participants who have an eGFR or measured CrCl of up to 10% below of either 5 0 
mL/min (for CrCl ) or 50 mL/min/1.73m2(for eGFR) may be enrolled in the study at the 
discretion of the investigator.
12.Has a history of significant multiple a nd/or severe allergies ( e.g., food, drug, latex 
allergy), or has had an anaphylactic reaction or significant intolerability ( i.e., systemic 
allergic reaction) to prescription or nonprescription drugs or food.
13.Previously developed severe EPS following administration of any prescribed medication 
or study treatment . Severe EPS is defined as follows: Parkinsonism type symptoms 
persisting for ≥ 3 days, or induction of a tremor that interferes with daily living, dystonia 
persisting for > [ADDRESS_111442] 1 unit of blood (approximately 500 mL) within 
4weeks prior to the prestudy (screening) visit.
Prior/Concomitant Th erapy
16.Has received treatment with monoamine oxidase inhibitors orunable to refrain from the 
use of co -medication with a moderate or strong inhibiting or inducing effect on CYP3A 
or moderate to strong inducing effect on CYP2C9 (CYP2C9 inhibitors are permit ted) 
beginning approximately [ADDRESS_111443]:   MK-8189  41
PROTOCOL/AMENDMENT NO.:   017 -04  
MK-8189 -017-04FINAL PROTOCOL 21-JUL-2022
Prior/Concurrent Clinical Study Experience
17.Has participated in another investigational study with in 4weeks (or 5 half-lives, 
whichever is greater) prior to the prestudy (screening) visit. The window will be derived 
from the date of the last visit in the previous study.
Diagnostic Assessments
18.Has a QTc interval >450 msec .
Other Exclusions
19.Does not agree to follow the smoking restrictions as defined by [CONTACT_47365].
20.Consumes greater than 3 glasses of alcoholic beverages (1 glass is approximately 
equivalent to: beer [354 mL/12 ounces], wine [118 mL/4 ounces], or distilled spi[INVESTIGATOR_2120] 
[29.5 mL/1 ounce]) per day . Participants who consume 4 glasses of alcoholic beverages 
per day may be enrolled at the discretion of the investigator.
21.Consumes excessive amounts, defined as greater than 6 servings (1 serving is 
approximately equivalent to 120 mg of caffeine) of coffe e, tea, cola, energy drinks, or 
other caffeinated beverages per day.
22.Is a regular user of cannabis, any illicit drugs or has a history of drug (including alcohol) 
abuse within approximately 3years. Participants must have a negative UDS (with the 
exception of cannabis and/or prescribed medications permitted at the discretion of the PI 
[INVESTIGATOR_80336] )prior to randomization.
23.Presents any concern by [CONTACT_100912].
24.Is or has an immediate family member (eg, spouse, parent/legal guardian, sibling, or 
child) who is investigational site or Sponsor staff directly involved with this study.
5.3 Lifestyle Considerations
5.3.1 Meals and Dietary Restrictions
[IP_ADDRESS] Diet Restrictions
Fasting requirements for laboratory safety evaluations are specified in Appendix 2.
Participants should fast overnight prior to allvisits to the CRU including the screening and 
poststudy vis its.  Otherwise ,participants will consume their usual diet except for grapefruit 
products (section [IP_ADDRESS]) . At CRU visits , participants may be given a light breakfast 
following study treatment administration.
08CG6Z
PRODUCT:   MK-8189  42
PROTOCOL/AMENDMENT NO.:   017 -04  
MK-8189 -017-04FINAL PROTOCOL 21-JUL-2022
[IP_ADDRESS] Fruit Juice Restrictions
Participants should refrain from the consumption of more than 1 grapefruit or 1 glass (8 
ounces) of grapefruit juice a day, throughout the entire study period. Otherwise, partici pants
canconsume their usual diet throughout the study period. 
5.3.2 Caffeine, Alcohol, and Tobacco Restrictions
[IP_ADDRESS] Caffeine Restrictions
Caffeinated beverages or xanthine -containing products will be limited to no more than 
6units per day (1 unit=120mg of caf feine).
[IP_ADDRESS] Alcohol Restrictions
Participants will refrain from consumption of alcohol 24 hours before all CRU visits 
including the screening and poststudy visits. A lcohol consumption is limited to no more than 
approximately 3 alcoholic beverages or equivalent servings (1serving is approximately 
equivalent to: beer [354 mL/12 ounces], wine [118 mL/4 ounces], or distilled spi[INVESTIGATOR_2120] 
[29.5 mL/1 ounce]) per day.
[IP_ADDRESS] Tobacco Restrictions
Participants will follow the smoking restrictions (and if applicable, the use of 
nicotine/nicotine -containing products) defined by [CONTACT_100913].
5.3.3 Activity Restrictions
Participants will avoid unaccustomed strenuous physical activity ( i.e., weightlifting, running, 
bicycling, etc .) from the screening visit until administration of the initial dose of study 
intervention, throughout the study and until the poststudy visit.
5.4 Screen Failures
Screen failures are defined as participants who consent to partici pate in the clinical study but 
are not subsequently randomized in the study. A minimal set of screen -failure information 
may be included, as outlined in the eCRF entry guidelines. Minimal information may include 
demography, screen -failure details, eligibil ity criteria, and any AEs or SAEs meeting 
reporting requirements.
5.5 Participant Replacement Strategy
If a participant discontinues from study intervention OR withdraws from the study a 
replacement participant may be enrolled if deemed appropriate by [CONTACT_100914]. The replacement participant will generally receive the same intervention or 
intervention sequence (as appropriate) as the participant being replaced. The replacement 
participant will be assigned a unique treatment/randomization number .
08CG6Z
PRODUCT:   MK-8189  43
PROTOCOL/AMENDMENT NO.:   017 -04  
MK-8189 -017-04FINAL PROTOCOL 21-JUL-2022
6 STUDY INTERVENTION
Study intervention is defined as any investigational intervention(s), marketed product(s), 
placebo, or me dical device(s) intended to be administered to a study participant according to 
the study protoco l.
Clinical supplie s (MK-8189/ placebo )will be packaged to support enrollment and 
replacement participants as required. When a replacement participant is required, the Sponsor 
or designee needs to be contact[CONTACT_100915] . Clinical supplies 
will be affixed with a clinical label in accordance with regulatory requirement s.
6.1 Study Intervention(s) Administered
The study intervention(s) to be used in this study are outlined in Table [ADDRESS_111444]: MK-8189  44
PROTOCOL/AMENDMENT NO.: 017-04
MK-8189 -017-04FINAL PROTOCOL 21-JUL-2022
Table 1 Study Intervention s
Arm 
NameArm 
TypeInter -
vention 
NameInter -
vention 
TypeDose 
Formu -
lationUnit Dose 
Strength(s)Dosage 
Level(s)Route of 
Admini -
strationRegimen/Treatment 
Period/Vaccination 
Regimen UseIMP/
NIMP Sourcing
Active Experi -
mentalMK-
8189Drug Tablet 4 mg
12 mgAll dosage 
levelsOral Titration s 1, 2 and 3 Experi -
mentalIMP Provided 
centrally
Placebo Placebo 
Compa r-
atorPlacebo Drug Tablet 0 mg All dosage 
levelsOral Titrations 1, 2 and 3 Experi -
mentalIMP Provided 
centrally
IMP=investigational medicinal product; NIMP=noninvestigational medicinal product .
The classification of I MP and N IMP in this table is based on guidance issued by [CONTACT_100916] E EA. Country differences with 
respect to the definition/classification of IMP/NIMP may exist. In these circumstances, local legislation is followed.
08CG6Z
PRODUCT: MK-8189  45
PROTOCOL/AMENDMENT NO.: 017-04
MK-8189 -017-04FINAL PROTOCOL 21-JUL-2022
All supplies indicated in Table 1 will be provided per the “Sourcing” column depending on 
local country operational requirements. If local sourcing, e very attempt should be made to 
source these supplies from a single lot/batch number where possible ( e.g., not applicable in 
the case where multiple lots or batches may be required due to the length of the study, etc).
Refer to Section 8.1.[ADDRESS_111445].
6.2 Preparation/Handling/Storage/Accountability
6.2.[ADDRESS_111446] be stored 
in a secure, environmentally controlled, and monitored (manual or automated) area in 
accordance with the labeled storage conditions with access limited to the investigator and 
authorized site staff.
The investigator, institution, or the head of the medical institution (where applicable) is 
responsible for study intervention accountability, reconciliation, and record maintenance (ie, 
receipt, reconciliation, and final disposition records).
For all study sites, the local country Sponsor personnel or designee will provide appropriate 
documentation that must be completed for drug accountability and return, or local discard 
and destruction if appropriate. Where local discard and destruction is appropriate, the 
investigator is responsible for ensuring that a local discard/destruction procedure is 
documented.
The study site is responsible for recording the lot number, manufacturer, and expi[INVESTIGATOR_19333] (if applicable) as per local guidelines unless otherwise 
instructed by [CONTACT_1034].
The investigator shall take responsibility for and shall take all steps to maintain appropriate 
records and ensure appropriate supply, storage, handling, distribution, and usage of study 
interventions in accordance with the protocol and any appli cable laws and regulation s.
08CG6Z
PRODUCT: MK-8189  46
PROTOCOL/AMENDMENT NO.: 017-04
MK-8189 -017-04FINAL PROTOCOL 21-JUL-2022
6.3 Measures to Minimize Bias: Randomization and Blinding
6.3.1 Intervention Assignment
Participants will be assigned randomly according to a computer -generated allocation 
schedule.
The sample allocation schedule is provided in Table 2.
Table 2 Sample Allocation Schedule
Titration 1
Days 1 -3 Days 4 -28
MK-8189 N=21 8 mg QD 16 mg QD
Placebo N=7 PBO PBO
Titration 2
Days 1 -3 Days 4 -6 Days 7 -28
MK-8189 N=21 8 mg QD 16 mg QD 24 mg QD
Placebo N=7 PBO PBO PBO
Titration 3
Days 1 -3 Days 4 -6 Days 7 -9 Days 10 -28
MK-8189 N=21 4 mg QD 8 mg QD 16 mg QD 24 mg QD
Placebo N=7 PBO PBO PBO PBO
Note: The allocation scheduled will be stratified to AD participants with and without agitation -aggression 
and/or psychosis symptoms . Participants without agitation -aggression and/or psychosis symptoms will be 
assigned starting at the low allocation range and participants with agitation -aggression and/or psychosis 
symptoms (defined as a severity score of ≥1 and frequency score ≥2 on the NPI [INVESTIGATOR_100887] -Aggression and/or 
Hallucination and/or Delusion domains) will be assigned star ting at the upper allocation range.
6.3.2 Stratification
Intervention allocation/randomization will be stratified according to the following factors:
1.participants with and without agitation- aggression and/or psychosis symptoms
For example, participants without agitation- aggression and/or psychosis symptoms will 
be assigned starting at the low allocation range and participants with agitation-
aggression and/or psychosis symptoms will be assigned starting at the upper allocation 
range. For t his protocol agitation -aggression and/or psychosis symptoms are defined as a 
severity score of ≥1 and frequency score of ≥2 on the NPI A gitation -Aggression and/or 
Delusions and/or Hallucinations d omains.
6.3.3 Blinding
A double -blinding technique with in-house blinding will be used. MK -8189 will be packaged 
identically to the matching placebo so that blind is maintained. The participant, thetrial 
partner/caregiver, the investigator, and Sponsor personnel or delegate(s) who are involved in 
08CG6Z
PRODUCT: MK-8189  47
PROTOCOL/AMENDMENT NO.: 017-04
MK-8189 -017-04FINAL PROTOCOL 21-JUL-2022
the study intervention administration or clinical evaluation of the parti cipants are unaware of 
the intervention assignments.
6.4 Study Intervention Compliance
Interruptions from the pr otocol -specified treatment plan require consultation between the 
investigator and the Sponsor and written documentation of the collaborative decision on 
participant management.
When participants self -administer study intervention(s) at home, daily phone ca lls will be 
made to check study intervention administration compliance. C ompliance with study 
intervention will also be assessed at each subsequent visit by[CONTACT_100917]/ trial partner/ caregiver . In addition, compliance will be monitored via counting 
of returned tablets at selected CRU visits and documented in the source documents and 
eCRF. Deviation(s) from the prescribed dosage regimen should be recorded i n the eCRF.
A record of the number of MK- 8189/ placebo tablets dispensed to and taken by [CONTACT_100918]. Intervention start dates, including dates for intervention delays and /or dose 
reductions will also be recorded in the CRF.
When participants are dosed at the site, study intervention administration will be 
witnessed by [CONTACT_17063]. The staff will witness the participant/trial partner/caregiver 
record the dosing in the study intervention diary. 
6.5 Concomitant Therapy
Concurrent use of any prescription or nonprescription medication, or concurrent vaccination 
during the ongoing study ( i.e., after randomization or intervention allocation) must first be 
discussed between the investigator and Sponsor prior to administration, unless appropriate 
medical care necessitates therapy or vaccination should begin before the investigator and 
Sponsor can c onsult. The participant will be allowed to continue in the study if both the 
Sponsor and the investigator agree.
Acetaminophen and antacids ( e.g., magnesium hydroxide) may be used for minor ailments 
without prior consultation with the Sponsor.
Moderate to strong inhibitors or inducers of CYP3A and moderate to strong inducers of 
CYP2C9 are not allowed as MK- [ADDRESS_111447]: MK-8189  48
PROTOCOL/AMENDMENT NO.: 017-04
MK-8189 -017-04FINAL PROTOCOL 21-JUL-2022
In addition, the following concomitant medications/vaccinations are permitted:
 Non- livevaccines may only beadministered inconsultation with theSponsor.
 COVID- [ADDRESS_111448] 48hours prior toanyCOVID- 19vaccination.
Exception: Investigational COVID- 19vaccines (i.e., those notlicensed orapproved
forEmergency Use) arenotallowed.
Continued Medication Use 
Participants may continue treatment with their prescribed cholinesterase inhibitors, 
memantine and aducanumab for the treatment of AD during the trial . The prescribed dose 
and regimen of medication must be stable for at least 3months prior to screening and there 
are no expected changes in co -medication during the study. 
In addition, medications to treat mild chronic conditions such as hypothyroidism, dia betes, 
high blood pressure, chronic respi[INVESTIGATOR_100893]. Forpermitted medications ,the prescribed dose and regimen of medication 
must be stable for at least 2 months prior to screening and there are no expected changes in 
co-medication during the study.
A participant ’s continued use of medications that may cause somnolence , including but not 
limited to benzodiazepi[INVESTIGATOR_100894] s,must be discussed between the 
investigator and the Sponsor prior to MK -8189 administration. 
6.5.1 Rescue Medications and Supportive Care
If over the course of the study behavioral symptoms worsen, if medically appropriate, the 
participant may be administered quetiapi[INVESTIGATOR_050] 50 mg .
6.6 Dose Modification (Escalation/Titration/Other)
The dose regimen for this trial is MK -8189 8 mg/placebo Days 1-3 days followed by 
16mg/placebo Days 4 -28(Titration 1) . 
Following MK -8189/placebo treatment of approximately [ADDRESS_111449]: MK-8189  49
PROTOCOL/AMENDMENT NO.: 017-04
MK-8189 -017-04FINAL PROTOCOL 21-JUL-2022
8 mg/matched placebo Days 1 -3, 16 mg/placebo Days 4 -6and24 mg/placebo Days 7 -28
(Titration 2)
4 mg/matched placebo Days 1 -3, 8 mg /placebo Days 4- 6, 16 mg/ placebo Days 7 -9 and 24 
mg/placebo Days 10- 28(Titration 3)
Other more conservative regimen
If medical care necessitates participants may:
Skip a single dose and dosing may continue at the same dose level or adjusted 
downwards .
Receive the same dose leve l to further explore safety and tolerability at that level .
Receive a lower dose of the study intervention .
Stop dosing.  
Any change in dosing regimen will be documented in a Protocol Clarification Letter.
6.7 Intervention After the End of the Study
There is no study- specified intervention after the end of the study.
6.8 Clinical Supplies Disclosure
The emergency unblinding call center will use the intervention allocation/randomization 
schedule for the study to unblind participants and to unmask study intervention identity. The 
emergency unblinding call center should only be used in cases of emergency (see Section 
8.1.10). The Sponsor will not provide random code/disclosure envelopes or lists with the 
clinical supplies.
6.[ADDRESS_111450] be collected through the participant’s last scheduled follow -up, even if 
the participant has discontinued study intervention. Therefore, all participants who 
discontinue study intervention before completion o fthe protocol -specified treatment regimen 
08CG6Z
PRODUCT: MK-8189  50
PROTOCOL/AMENDMENT NO.: 017-[ADDRESS_111451] 
occur. In addition, a participant may be discontinued from study intervention by [CONTACT_100919] e, the study plan is violated, or 
for administrative and/or other safety reasons. Specific details regarding procedures to be 
performed at study intervention discontinuation are provided in Section 8.1.9.
A participant must be discontinued from study inter vention, but continue to be monitored in 
the study, for any of the following reasons:
•The participant or participant’s legally acceptable representative requests to discontinue 
study intervention.
•The participant’s treatment assignment has been unblinded by [CONTACT_093], or through 
the emergency unblinding call center.
•The participant interrupts study intervention administration for more than 2consecutive 
days or has 4 cumulative missed doses.
•The participant has a medical condition or perso nal circumstance which, in the opi[INVESTIGATOR_19348]/or Sponsor, placed the participant at unnecessary risk from continued 
administration of study intervention.
•The participant has a positive UDS except for allowed concomitant medication 
administ ered during trial, at any time during the study. The drug screen can be confirmed 
by a recheck at the discretion of the investigator after discussion with the Sponsor.
•Any participant with EPS requiring treatment that is not or cannot be managed by [CONTACT_100920].
•The participant no longer has a trial partner/caregiver or the trial partner/caregiver 
withdraws consent and a substitute cannot be identified.
Discontinuation from study intervention is “permanent.” Once a participant is discontinued
from study inte rvention , they shall not be allowed to restart study intervention .
7.[ADDRESS_111452] be withdrawn from the study if the participant or participant’s legally 
acceptable representative withdraws consent from the study.
If a participant withdraws from the study, they will no longer receive study intervention or be 
followed at scheduled protocol visits.
08CG6Z
PRODUCT: MK-8189  51
PROTOCOL/AMENDMENT NO.: 017-04
MK-8189 -017-04FINAL PROTOCOL 21-JUL-2022
Specific details regarding procedures to be performed at the time of withdrawal from the 
study, as well as specific det ails regarding withdrawal from FBR ,are outlined in Section 
8.1.9. The procedures to be performed should a participant repeatedly fail to return for 
scheduled visits and/or if the study site is unable to contact [CONTACT_88683] 7.3.
7.[ADDRESS_111453] t o Follow -up
If a participant fails to return to the clinic for a required study visit and/or if the site is unable 
to contact [CONTACT_2299], the following procedures are to be performed:
•The site must attempt to contact [CONTACT_100921]. If the 
participant is contact[INVESTIGATOR_530], the participant should be counseled on the importance of 
maintaining the protocol -specified visit schedule.
•The investigator or designee must make every effort to regain contact [CONTACT_100922] (eg, telephone calls and/or a certified letter to the participant’s last 
known mailing address or locally equivalent methods). These contact [CONTACT_19425]’s medical record.
•Note: A participant is not considered lost to follow -up until the last scheduled visit for the 
individual participant. The missing data for the participant will be managed via the 
prespecified statistical data handling and analysis guidelines .
8 STUDY ASSESSMENTS AND PROCEDURES
•Study pr ocedures and their timing are summarized in the SoA.
•Adherence to the study design requirements, including those specified in the SoA, is 
essential and required for study conduct.
•The investigator is responsible for ensuring that procedures are conducted by 
[CONTACT_19426] (by [CONTACT_8640], training, and experience) staff. Delegation of 
study- site personnel responsibilities will be docu mented in the Investigator Trial File 
Binder (or equivalent).
•All study- related medica l decisions must be made by [CONTACT_19427] a qualified 
physician.
•All screening evaluations must be completed and reviewed to confirm that potential 
participants meet all eligibility criteria. The investigator will maintain a screening log to 
record details of all participants screened and to confirm eligibility or record reasons for 
screening failure, as applicable.
•Procedures conducted as part of the participant’s routine clinical management (eg, blood 
count) and obtained before signing of ICF may be u sed for screening or baseline purposes 
provided the procedure met the protocol -specified criteria and were performed within the 
time frame defined in the SoA.
08CG6Z
PRODUCT: MK-8189  52
PROTOCOL/AMENDMENT NO.: 017-04
MK-8189 -017-04FINAL PROTOCOL 21-JUL-2022
•Additional evaluations/testing may be deemed necessary by [CONTACT_100923] p articipant safety. In some cases, such evaluation/testing 
may be potentially sensitive in nature (eg, HIV, hepatitis C), and thus local regulations 
may require that additional informed consent be obtained from the participant. In these 
cases, such evaluati ons/testing will be performed in accordance with those regulations.
The maximum amount of blood collected from each participant over the duration of the study
will not exceed 193.5mL(Appendix 8).
Repeat or unscheduled samples may be taken for safety reasons or for technical issues with 
the samples.
8.1 Administrative and General Procedures
8.1.1 Informed Consent
The investigator or medically qualified designee (consistent with local requirements) must 
obtain documented informed consent from each potential participa nt (or their legally 
acceptable representative ) prior to participating in thisclinical study or FBR . If there are 
changes to the participant’s status during the study (eg, health or age of majority 
requirements), the investigator or medically qualified de signee must ensure the appropriate 
documented informed consent is in place.
[IP_ADDRESS] General Informed Consent
Informed c onsent given by [CONTACT_19429] a consent form . The form must include the study protocol number, study 
protocol title, dated signature , and agreement of the participant ( orhis/her leg ally acceptable 
representative ) and of the person conducting the consent discussion.
A copy of the signed and dated informed consent form should be given to the participant (or 
their legally acceptable representative) before participation in the study.
The initial ICF, any subsequent revised ICF, and any written information provided to the 
participant must receive the IRB /IEC’s approval/favorable opi[INVESTIGATOR_19349]. The 
participant or his/her legally acceptable representative should be informed in a timely manner 
if new information becomes available that may be relevant to the participant’s willingness to 
continue p articipation in the study. The communication of this information will be provided 
and documented via a revised consent form or addendum to the original consent form that 
captures the participant’s or the participant’s legally acceptable representative’s da ted 
signature.
Documented informed consent from each participant’s trial partner/caregiver (referred to as
trialpartner informed consent) will also be obtained by [CONTACT_27404].
Specifics about the study and the study population a reto be included in thestudy informed
consent form.
08CG6Z
PRODUCT: MK-8189  53
PROTOCOL/AMENDMENT NO.: 017-04
MK-8189 -017-04FINAL PROTOCOL 21-JUL-2022
Informed consent will adhere to IRB/IEC requirements, applicable laws and regulations, and 
Sponsor requirements .
[IP_ADDRESS] Consent and Collection of Specimens for Future Biomedical Research
The investigator or me dically quali fied designee will explain the FBR consent to the 
participant, or the participant’s legally acceptable representative, answer all of his/her 
questions, and obtain documented informed consent before performing any procedure related 
to FBR . A co py of the informed consent will be given to the participant before performing 
any procedure related to FBR .
8.1.2 Inclusion/Exclusion Criteria
All inclusion and exclusion criteria will be reviewed by [CONTACT_093] ,who is a qualified 
physician, to ensure that the participant qualifies for the study.
8.1.[ADDRESS_111454] information (including direct 
telephone numbers) to be used in the event of an emergency. The investigator or qualified 
designee will provide the participant with a participant identification card immediately after 
the participant provides documented informed consent . At the time of intervention
randomization, site personnel will add the treatment /randomization number to the participant 
identification card.
The participant identification card also contains contact [CONTACT_19430] a health care provider can obtain information about study 
intervention in emergency situations where the investigator is not available.
8.1.4 Medical History
A medical history , including psychiatric history and substance usage , will be obtained by [CONTACT_100924].
8.1.5 Prior and Concomitant Medications Revi ew
[IP_ADDRESS] Prior Medications
The investigator or qualified designee will review and record medication s taken by [CONTACT_100925] 3 months of the Screening visit. 
[IP_ADDRESS] Concomitant Medications
The investigator or qualified designee will record medication, if any, taken by [CONTACT_19432].
08CG6Z
PRODUCT: MK-8189  54
PROTOCOL/AMENDMENT NO.: 017-[ADDRESS_111455] not be re used for 
different participants.
Any participant who is screened multiple times will retain the original screening number 
assigned at the initial Screening V isit. Specific details on the screening/rescreening visit 
requirements are in Section 8.10.2.
8.1.7 Assignment of Treatment/ Randomization Numb er
All eligible participants will be randomly allocated and will receive a 
treatment /randomization number. The treatment/randomization number identifies the 
participant for all procedures occurring after treatment alloc ation/randomization . Once a 
treatment /randomization number is assigned to a participant, it can never be reassigned to 
another participant.
A single participant cannot be assigned more than 1 treatment /randomization number.
Refer to the study operations ma nual for detailed procedures for requesting a 
treatment/randomization number.
8.1.[ADDRESS_111456] ration of each study intervention titration.  
Supervision willbe done by [CONTACT_7893] . 
Participants will receive bottle(s) of study intervention on Day 1 and at each CRU visit.  
Prior to dispensing a new bottle of study intervention, the previous bottl e dispensed will be 
collected. Each bottle will contain enough study intervention to cover the duration between 
each CRU visit.
Participants and their trial partner/ caregiver will be instructed on how to administer at home 
study intervention by [CONTACT_100926].  
[IP_ADDRESS] Timing of Dose Administration
Study intervention should be administered orally in the morning at approximately the same 
time each day. Study intervention will be administered fasted (in CRU) or with/without food 
(at home) with approximately [ADDRESS_111457]: MK-8189  55
PROTOCOL/AMENDMENT NO.: 017-04
MK-8189 -017-04FINAL PROTOCOL 21-JUL-2022
Trial partners/ caregivers will record time of dosing in a study intervention dosing diary.  On 
days when study intervention is administered in the CRU, dose administration will be 
witnessed by [CONTACT_1755]/or study staff.
8.1.[ADDRESS_111458] notify the Sponsor when a participant has been 
discontinued/withdrawn from the study and/or intervention. If a participant discontinues for 
any reason at any time during the course of the study and/or intervention, the participant may 
be asked to return to the clinic (or be contact[INVESTIGATOR_530]) for a poststudy visit as per the number of 
days described in Section 8.10.[ADDRESS_111459] the applicable procedures conducted. However, the 
investigator may decide to perform the poststudy procedures at the time of discontinuation or 
as soon as possible after discontinuation. If the poststudy visit occurs prior to the safety 
follow -up tim e frame as specified in Section 8. 4.1, the investigator should perform a follow -
up telephone call at the end of the follow -up period (Section 8.4 .1) to confirm if any AEs 
have occurred since the poststudy clinic visit. Any AEs that are present at the time of 
discontinuation/withdrawal should be followed in accordance with the safety requirements 
outlined in Section 8. 4.
[IP_ADDRESS] Withdrawal From Future Biomedical Resear ch
Participants may withdraw their consent for FBR . Participants may withdraw consent at any 
time b y contact[CONTACT_100927]. If medical records for the study are still available, 
the investigator will contact [CONTACT_75355] 
([EMAIL_1250]). Subsequently, the participant’s consent for 
FBR willbe withdrawn. A letter will be sent from the Sponsor to the investigator confirming 
the withdrawal. It is the responsibility of the investigator to inform the participant of 
completion of withdrawal. Any analyses in progress at the time of request for wit hdrawal or 
already performed before the request being received by [CONTACT_88691]. No new analyses would be generated 
after the request is received.
If the medical records for the study are no longer available (eg, if the investigator is no longer 
required by [CONTACT_88692]) or the specimens have been 
completely anonymized, there will no longer be a link between the participant’s personal 
informat ion and their specimens. In this situation, the request for specimen withdrawal 
cannot be processed .
8.1.10 Participant Blinding/Unblindi ng
STUDY INTERVENTION IDENTIFICATION INFORMATION IS TO BE UNMASKED 
ONLY IF NECESSARY FOR THE WELFARE OF THE PARTICIPANT. EVERY
EFFORT SHOULD BE MADE NOT TO UNBLIND.
For emergency situations where the investigator or medically qualified designee (consistent 
with local requirements) needs to identify the intervention used by a participant and/or the 
dosage administered, he/ she will contact [CONTACT_100928] 
08CG6Z
PRODUCT: MK-8189  56
PROTOCOL/AMENDMENT NO.: 017-[ADDRESS_111460] for emergency unblinding. As requested by [CONTACT_19445] , the emergency unblinding call center will provide the informa tion to 
him/her promptly and report unblinding to the Sponsor. Before contact[CONTACT_88694] a participant’s intervention assignment, the 
investigator who is qualified physician should make reasonable attem pts to enter the intensity
of the AEs observed, th e relation to study intervention , the reason thereof, etc, in the medical 
record . If it is not possible to record this assessment in the medical record before the 
unblinding, the unblinding should not be de layed.
If unblinding has occurred, the circumstances around the unblinding (eg, date, reason, and 
person performing the unblinding) must be documented promptly, and the Sponsor Clinical 
Director notified as soon as possible.
Once an emergency unblinding ha s taken place, the investigator, site personnel, and Sponsor 
personnel may be unblinded so that the appropriate follow -up medical care can be provided 
to the participant.
Participants whose treatment assignment has been unblinded by [CONTACT_941] i nvestigator or med ically 
qualified designee and/or non study treating physician must be discontinued from study 
intervention, but should continue to be monitored in the study.
8.1.11 Calibration of Equipme nt
The investigator or qualified designee has the responsibility to ensure th at any device or 
instrument used for a clinical evaluation/test during a clinica l study that provides information 
about inclusion/exclusion criteria and/or safety or efficacy parameters shall be suitably 
calibrated and/or maintained to ensure that the data obtained are reliable and/or reproducible. 
Documentation of equipment calibration must be retained as source documentation at the 
study sit e.
8.1.12 Domiciling (optional)
For sites that have domiciling capability to keep participants overnight, the site may offe r
study participants the option to stay in the CRU for the duration of the titration period or the 
entire intervention period (Day 1 -28). Any other domiciling period will need to be discussed 
with the Sponsor. The stud y partner /caregiver is not required to stay overnight but may do so 
if requested by [CONTACT_100929].
At the discretion of the investigator, participants will report to the CRU the evening before 
Day 1 andremain in theCRU until after thecompletion of study procedures onDay 7 
(Titration 1 and Titration 2)/Day 10 (Titration 3) or Day [ADDRESS_111461] the unit, for emergency situations only, at the discretion of the investigator after 
discussion with the Sponsor.
Study staff will also witness the study medication and work with the participants /trial 
partners/caregivers in completing the dosing diary when the participants are in the CRU.
08CG6Z
PRODUCT: MK-8189  57
PROTOCOL/AMENDMENT NO.: 017-[ADDRESS_111462] efficacy assessments in this study .
8.3 Safety Assessments
Details regarding specific safety procedures/assessments to be performed in this study are 
provided below . The total amount of blood to be drawn over the course of the study (from 
screening to poststudy visits), including approximate blood volumes drawn by [CONTACT_100930], can be found in Appendix 8.
Planned time points for all safety assessments are provided in the SoA.
8.3.1 Physical Examinations
A complete physical examination will be conducted by [CONTACT_88696] (consistent with local requirements) per institutional standard. Height and weight 
will also be measured and recorded.
Investigators should pay special attention to clinical signs related to previous serious 
illnesses.
BMI
BMI equals a person's weight in kilograms divided by [CONTACT_55739] 
(BMI=kg/m2). BMIwill be rounded to the nearest whole number according to the standard 
convention of 0.1 to 0.4 round down and 0.5 to 0.9 round up.
Body weight and height will be obtained with the participant’s shoes off and jacket or coat 
removed.
8.3.2 Vital Signs
[IP_ADDRESS] Resting Vital Signs
Pulse Rate ,Blood Pressure , Respi[INVESTIGATOR_100895] a quiet setting without distractions in a semi -recumbent 
position for at least [ADDRESS_111463] positioning on the 
participants' arm is essential to increase the accuracy of BP measurements.
The Screening and Day 1 predose ( prior to dose ) pulse rat eand BP will be triplicate 
measurements, obtained at least [ADDRESS_111464]: MK-8189  58
PROTOCOL/AMENDMENT NO.: 017-04
MK-8189 -017-04FINAL PROTOCOL 21-JUL-2022
measurement will be taken within 3 hours prior to dosing MK -8189 /placebo . The mean of 
these measurements will be used as the baseline to calcula te change from baseline for safety 
evaluations (and for rechecks, if needed). AllVS measurements after Day [ADDRESS_111465] be used for all measurements for each individual 
participant and should be the same for all participants.
[IP_ADDRESS] Orthostatic Vital Signs
Orthostatic VS ( pulse rate andsystolic and diastolic BP) will also be obtained. Participants 
should be semi -recumbent for at least [ADDRESS_111466] 1 to 2 minutes apart within 3 hours 
before dosing MK -8189. The mean of these measurements will be used as the baseline t o 
calculate change from baseline for safety evaluations (and for rechecks, if needed).
If a participant demonstrates an increase in QTc interval ≥60msec compared with mean 
baseline measurement, the ECG will be repeated twice within 5 minutes. The mean value of 
the QTc interval from the 3 ECGs will represent the value at that time point. If the mean QTc 
interval increase from baseline for any postdose time point is ≥[ADDRESS_111467] 1 hour or until 
the QTc is within 60 msec of baseline. If prolongation of the QTc interval ≥[ADDRESS_111468] may be appropriate and the Sponsor should be 
notified.
If a participant demonstrates a QTc interval ≥500msec on a postdose ECG , the ECG will be 
repeated twice within 5 minutes. Themean value of the QTc interval from the 3 ECGs will 
represent the value at that time point. If the mean QTc interval is ≥[ADDRESS_111469]: MK-8189  59
PROTOCOL/AMENDMENT NO.: 017-04
MK-8189 -017-04FINAL PROTOCOL 21-JUL-2022
should be telemetry monitored ( until the QTc is <500 msec ) or should be considered for 
transfer to a location where closer monitoring and definitive care (eg, a CCU or ICU) is 
available.
If the participant has unstable hemodynamics, or has any clinically significant dysrhythmias 
noted on telemetry, the participant should be immediately transferred to an acute care setting 
for definitive therapy.
If prolongation of the QTc is not ed, concomitant medications that prolong QTc should be 
held until the QTc is within 60 msec of baseline and the QTc is <[ADDRESS_111470] of clinical laboratory tests to be performed and to the SoA for 
the timing and frequency.
•The investigator or medically qualified designee (consistent with local requirements) 
must review the laboratory report, document this review, and record any clinically 
relevant changes occurring during the study in the AE section of the CRF. The laboratory 
reports must be filed with the source documents. Clinically significant abnormal 
laboratory findings are those which are not associated with the underlying disease, unless 
judged by [CONTACT_19448] ’s condition.
•All protocol -required laboratory assessments, as defined in Appendix [ADDRESS_111471] be 
conducted in accordance with thelaboratory manual and the SoA .
•If laboratory values from nonprotocol -specified laboratory assessments performed at the 
institution’s local laboratory require a change in study participant management or are 
considered clinically signifi cant by [CONTACT_093] (eg, SAE or AE or dose 
modification), then the results must be recorded in the appropriate CRF (eg, SLAB).
•For any laboratory tests with values considered clinically significantly abnormal during 
participation in the study or within 14days after the last dose of study intervention, every 
attempt should be made to perform repeat assessments until the values return to normal or 
baseline or if a new baseline is established as determined by [CONTACT_093] .
8.3.5 Pregnancy Testing
•Pregnancy testing:
-Pregnancy testing requirements for study inclusion are described in Section 5.1.
-Additional serum or urine pregnancy tests may be performed, as determined 
necessary by [CONTACT_31837], to establish the absenc e 
of pregnancy at any time during the subject's participation in the study.
08CG6Z
PRODUCT: MK-8189  60
PROTOCOL/AMENDMENT NO.: 017-04
MK-8189 -017-04FINAL PROTOCOL 21-JUL-2022
8.3.6 Suicidal Ideation and Behavior Monitoring
[IP_ADDRESS] Clinical Assessments for Suicidal Ideation and Behavior Monitoring
Suicidal ideation and behavior will be prospectively assessed during this study using the C -
SSRS. The C -SSRS should be administere d by [CONTACT_88698] S oA. In addition, C -SSRS will be administered at any unscheduled visit where safety 
assessments are performed. The C -SSRS will not b e routinely administered at visits with a 
sole purpose of PK sampling and/or witnessed study intervention administration. Site staff 
should review the con tents of the C -SSRS for complete ness.
If the C -SSRS is administered by [CONTACT_100931], consider providing the 
completed C -SSRS to the investigator for review, before their assessment of the participant 
and to further inform their evaluation.
The C -SSRS is not explicit about whether the participant specifically has ideation at the time 
of screening. If a participant reports a prior history of ideation/behavior at screening, the 
assessor should also inquire and document if this is also present at the time of the Screening 
Visit.
Participants who at any time during this study report suicid al ideation or behavior that is 
considered to be an AE, either between visits or during visit interviews, must be assessed by 
[CONTACT_093]. Participants who report suicidal ideation with intent, with or without a plan 
or method ( i.e., a positive response to items 4 or 5 in the assessment of suicidal ideation on 
the C -SSRS) or suicidal behavior must be evaluated that day by a psychiatrist or other trained 
mental health professional who is a licensed psychologist, social worker, or mental health 
nurse practitioner (or comparable professional qualification in countries outside the United 
States). After that evaluation, only those participants whose suicidal ideation is considered by 
[CONTACT_88700], and who expressly deny any intent to act, and who, after 
evaluation, are not judged to be at serious risk for self -harm during the course of the study 
may continue in the study; o ther participants must be discontinued from study participation 
and receive appropriate clinical follow -up care to ensure their safety. In addition, all AEs of 
suicidal ideation or behavior must be recorded as an ECI (See Section 8.4.7). Sites are to 
designate which health care professionals are to be responsible for acute care on -site and to 
specify referra l center(s) to be used for further evaluation.
8.3.7 Rater Expectations and Training for Clinical and Cognitive Assessments
For this study ,potential raters of clinical and/or cognitive assessments (BARS [Section 
8.3.11 ], SAS [Section 8.3.11 ], AIMS [Section 8.3. 11], C-SSRS [8.3.6 .1], MHIS [Section 
8.3.8 ], MMSE -2[Section 8.3.9] , and NPI[Section 8.3. 10]) will be identified based onreview 
of their reported credentials against target minimum credentials for education, prior 
experience with AD, MCI or similar popul ations and direct, hands -on experience with study-
specific or similar assessments .  Persons whose credentials meet or exceed those targets will 
then be considered ‘qualified’ as raters in this trial.  For the MMSE -[ADDRESS_111472]: MK-8189  61
PROTOCOL/AMENDMENT NO.: 017-[ADDRESS_111473] provided by [CONTACT_47365].   
8.3.8 Rosen -Modified Hachinski Ischemia Scale
The MHIS will be completed by a nexperienced rater at timepoints specified in Section 1.3 
Schedule of Activities . 
8.3.9 Mini Mental State Examination Second Edition
The paper version of the MMSE-2 (Standard version, both Red and Blue forms) will be 
administered and scored by a qualified, trained rater at timepoints specified in Section 1.3 
Schedule of Activities . Additional information concerning administration, scoring and 
documentation may also be provided in rater training and in the MOA.
8.3.10 Neuropsychiatric Inventory
The paper version of the NPI(12 items) will be administered by a qual ified, trained rater at 
timepoints specified in Section 1.3 Schedule of Activities . Additional information concerning 
administration, scoring and documentation may also be provided in rater training and in the 
MOA.
8.3.11 Monitoring of Extrapyramidal Symptoms
TheBarnes Akathisia Ratting Scale ( BARS ), Abnormal Involuntary Movement Scale 
(AIMS) and Simpson Angus Scale (SAS) will be completed by a qualified rater at timepoints 
specified in Section 1.3 Schedule of Activities .
Refer to the MOA for additional informati on regarding the BARS, AIMS and SAS.
8.3.12 Neurological Exam
The General (Full) Neurological Exam will be perf ormed at the Screening and Baseline 
visits.  The Targeted Neurological Exam will be administered at times specified in the SoA.  
TheGeneral and T argeted Neurological Exams are contained in Appendix 10.
8.[ADDRESS_111474]: MK-8189  62
PROTOCOL/AMENDMENT NO.: 017-04
MK-8189 -017-04FINAL PROTOCOL 21-JUL-2022
Adverse events, SAEs, and other reportable safety events will be reported by [CONTACT_2299] 
(or, when appropriate, by a caregiver, surrogate, or the participant's legally authorized 
representative).
The investigator and any designees are responsible for detecting, documenting, and reporting 
events that meet the definition of an AE or SAE as well as other reportable safety e vents. 
Investigators remain responsible for following up AEs , SAEs, and other reportable safety 
events for outcome according to Section 8.4.3.
The investigator, who is a qualified physician, will assess events that meet the definition of 
an AE or SAE as we ll as other reportable safety events with respect to seriousness, 
intensity/toxicity and causality .
8.4.1 Time Period and Frequency for Collecting AE, SAE ,and Other Reportable 
Safety Event Information
AEs, SAEs, and other reportable safety events that occur aft er the participant provides 
documented informed consent , but before intervention allocation/randomization, must be 
reported by [CONTACT_100932], or is the re sult of a protocol -specified intervention, 
including ,but not limited to washout or discontinuation of usual therapy, diet, placebo, or a 
procedure.
From the time of intervention allocation/randomization through [ADDRESS_111475] be reported immediately to the S ponsor if the 
event is considered related to study intervention .
Investigators are not obligated to actively seek AE sor SAEs or other reportable safety events 
in former study participants. However, if the investigator learns of any SAE, including a 
death, at any time after a participant has been discharged from the study, and he/she 
considers the event to be reasonably related to the study intervention or study participation, 
the investigator must promptly notify the Sponsor.
All initial and follow -up AEs, SAEs, and other reportable safety events will be recorded and 
reported to the Sponsor or designee within the time frames as indicated in Table 3 .
Exception: A positive pregnancy test at the time of initial screening is not a reportable event 
unless the participant has received study intervent ion.
08CG6Z
PRODUCT: MK-8189  63
PROTOCOL/AMENDMENT NO.: 017-04
MK-8189 -017-04FINAL PROTOCOL 21-JUL-2022
Table 3 Reporting Time Periods and Time Frames for A dverse Events and Other 
Reportable Safety Events
Type of 
EventReporting Time 
Period:
Consent to 
Randomization/ 
Allocation
(Randomized 
participants only)Reporting Time 
Period:
Randomization/ 
Allocation 
through Protocol -
specified Follow -
up PeriodReporting Time 
Period:
After the 
Protocol -
specified Follow -
up PeriodTime Frame to 
Report Event and 
Follow -up 
Information to 
Sponsor:
NSAE Report if:
-due to protocol -
specified intervention
-causes exclusion
-participant is receiving 
placebo run -in or other 
run-in treatmentReport all Not required Per data entry 
guidelines
SAE Report if:
-due to protocol -
specified intervention
-causes exclusion
-participant is receiving 
placebo run -in or other 
run-in treatmentReport all Report if:
-drug/vaccine 
related.
(Follow ongoing 
to outcome)Within 24 hours of 
learning of event
Pregnancy/
Lactation 
ExposureReport if:
-participant has been 
exposed to any protocol -
specified intervention 
(eg, procedure, washout 
or run -in treatment 
including placebo run -in)
Exception: A positive 
pregnancy test at the 
time of initial screening 
is not a reportable event.Report all Previously 
reported – Follow 
to completion/
termination; report 
outcomeWithin 24 hours of 
learning of event
ECI (require 
regulatory 
reporting)Report if:
-due to intervention
-causes exclusionReport
-potential DILI
-require regulatory 
reportingNot required Within 24 hours of 
learning of event
ECI (do not 
require 
regulatory 
reporting)Report if:
-due to intervention
-causes exclusionReport
-non-DILI ECIs 
and those not 
requiring 
regulatory 
reportingNot required Within 5 calendar 
days of learning of 
event
Cancer Report if:
-due to in tervention
-causes exclusionReport all Not required Within 5 calendar 
days of learning of 
event
(unless serious)
08CG6Z
PRODUCT: MK-8189  64
PROTOCOL/AMENDMENT NO.: 017-04
MK-8189 -017-04FINAL PROTOCOL 21-JUL-2022
Type of 
EventReporting Time 
Period:
Consent to 
Randomization/ 
Allocation
(Randomized 
participants only)Reporting Time 
Period:
Randomization/ 
Allocation 
through Protocol -
specified Follow -
up PeriodReporting Time 
Period:
After the 
Protocol -
specified Follow -
up PeriodTime Frame to 
Report Event and 
Follow -up 
Information to 
Sponsor:
Overdose Report if:
-receiving placebo run -
in or other run -in 
medication Report all Not required Within 24 hours of 
learning of event
DILI=drug -induced liver injury; ECI=event of clinical interest; NSAE=nonserious adverse event; SAE=serious adverse 
even t.
8.4.2 Method of Detecting AE s, SAE s,and Other Reportable Safety Events
Care will be taken not to introduce bias when detecting AE sand/or S AEsand other 
reportable safety events. Open- ended and nonleading verbal questioning of the participant is 
the preferred method to inquire about AE occurrence.
8.4.3 Follow -up of AE, SAE ,and Other Reportable Safety Event Information
After the initial AE/SAE report, the investigator is required to proactively follow each 
participant at subsequent visits/contacts. All AE s, SAE s, and other reportable safety events,
including pregnancy and exposure during breastfeeding, ECI s, cancer, and overdose will be 
followed until resolution, stabilization, until the event is otherwise explained, or the 
participant is lost to follow -up (as defined in Section 7.3 ). In addition, the investigator will 
make e very attempt to follow all nonserious AEs that occur in randomized participants for 
outcome. Further information on follow -up procedures is given in Appendix 3.
8.4.4 Regulatory Reporting Requirements for SAE
Prompt notification (within 24 hours) by [CONTACT_100933] a study intervention under clinical investigation are met.
The Sponsor has a legal responsibility to notify both the local regulatory authority and other 
regulatory agencies about the safety of a study intervention under clinical investigation. The 
Sponsor will comply w ith country -specific regulatory requirements and global laws and 
regulations relating to safet y reporting to regulatory authorities, IRB/IECs, and investigators.
Investigator safety reports must be prepared for S[LOCATION_003]R saccording to local regulatory 
requirements and Sponsor policy and forwarded to investigators as necessary.
An investigator who recei ves an investigator safety report describing an SAE or other 
specific safety information (eg, summary or listing of SAE) from the Sponsor will file it 
along with the I Band will notify the IRB/IEC, if appropriate according to local requirements .
08CG6Z
PRODUCT: MK-8189  65
PROTOCOL/AMENDMENT NO.: 017-04
MK-8189 -017-04FINAL PROTOCOL 21-JUL-2022
8.4.5 Pregnancy and Exposure During Breastfeeding
Not applicable
8.4.6 Disease -related Events and/or Disease -related Outcomes Not Qualifying as 
AEs or SAEs
Not applicable
8.4.[ADDRESS_111476] for this study include:
1.An overdose of Sponsor's product, as defined in Section 8.5.
2.An elevated AST or ALT laboratory value that is greater than or equal to 3X the ULN 
and an elevated total bilirubin laboratory value that is greater than or equal to 2X the 
ULN and, at the same time, an alkaline phosphatase laboratory value that is less than 2X 
the ULN, as determined by [CONTACT_13149] -specified laboratory testing or unscheduled 
laboratory testing.*
*Note : These criteria are based on available regulatory guidance documents. The purpose 
of the criteria is to specify a threshold of abnormal hepatic tests that may require an 
additional evaluation for an underlying etiology. The study -site guidance for assessm ent 
and follow up of these criteria can be found in the Investigator Study File Binder (or 
equivalent).
It may also be appropriate to conduct additional evaluation for an underlying etiology in the 
setting of abnormalities of liver blood tests including AS T, ALT, bilirubin, and alkaline 
phosphatase that do not meet the criteria noted above. In these cases, the decision to proceed 
with additional evaluation will be made through consultation between the study investigators 
and the Sponsor Clinical Director. H owever, abnormalities of liver blood tests that do not 
meet the criteria noted above are not ECIs for this study.
3.Severe EPS or EPS resulting in study intervention discontinuation
4.Suicidal ideation, suicidal behavior
5.Treatment -emergent adverse event of new or worsening tardive dyskinesia
8.[ADDRESS_111477]: MK-8189  66
PROTOCOL/AMENDMENT NO.: 017-04
MK-8189 -017-04FINAL PROTOCOL 21-JUL-2022
or the reporting physician to decide whether a dose is to be consi dered an overdose, in 
consultation with the Sponsor.
8.6 Pharmacokinetics
The decision as to which plasma samples collected will be measured for evaluation of PK 
will be collaboratively determined by [CONTACT_1034] ( e.g., samples at lower doses may not be 
measure dif samples at higher doses reveal undetectable drug concentrations). If indicated, 
these samples may also be measured and/or pooled for assay in an exploratory manner for 
metabolites and/or additional pharmacodynamic markers .
8.6.1 Bloo d Collection for Plasma MK -8189 and/or Metabolites Assay
Sample collection, storage, and shipment instructions for plasma samples will be provided in 
the laboratory m anual .
8.6.2 Bloo d Collection for Plasma Donepezil Assay
Sample collection, storage, and shipment instructions will be provided in the laboratory
manual .
8.6.3 Blood Collection for Plasma Memantine Assay
Sample collection, storage, and shipment instructions will be provided in the laboratory
manual .
8.7 Pharmacodynamics
Pharmacodynamic parameters will not be evaluated in this study.
8.8 Biomarkers
Collection of samples for other biomarker research is also part of this study. The following 
samples for biomarker research are required and will be collected from all participants a s 
specified in the SoA:
•Blood for Genetic Analysis
•Blood for Exploratory Plasma Biomarkers for AD Diagnosis
8.8.1 Planned Genetic Analysis Sample Collection
The planned genetic a nalysis sample will be drawn for CYP2C9 genotypi[INVESTIGATOR_88645]. If the 
IRB/IEC does not approve of the planned analysis of the association between DNA variation 
and drug response, or if there is a local law or regulation prohibiting the same, data analy sis 
will be limited to CYP2C9 genotypi[INVESTIGATOR_007] . Leftover extracted DNA will be stored for FBR if the 
participant provides documented informed consent for FBR .
08CG6Z
PRODUCT: MK-8189  67
PROTOCOL/AMENDMENT NO.: 017-04
MK-8189 -017-04FINAL PROTOCOL 21-JUL-2022
Sample collection, storage, and shipment instructions for planned genetic a nalysis samples 
will be in the operations/laboratory manual .
8.8.2 Exploratory Plasma Biomarkers for Alzheimer’s Disease Diagnosis Sample 
Collection
Sample collection, storage, and shipment instructions for exploratory plasma biomarker
samples will be provided in the operations/laboratory manual.
8.9 Future Biomedical Research Sample Collection
If the participant provides documented informed consent for FBR , the following specime ns 
will be obtained as part of FBR :
•Leftover DNA for future research
•Leftover main study plasma from MK -8189 and/or metabolites assay stored for future 
research.
8.10 Visit Requirements
Visit requirements are outlined in Section 1.3. Specific procedure -related details areprovided 
inSection 8.
8.10.1 Trial Partner /Caregiver Participation
The trialpartner/ caregiver is required to accompany the participant to the Screening Visit, to
sign the trial partner informed consent. This trialpartner /caregiver should be willing and 
make every effort to accompany the participant to allstudy visits .In the e vent the trial 
partner/caregiver in unable to attend a study visit , he/she should discuss alternative 
arrangements with the site (e.g., participant transportation, return of study intervention and 
dosing diary) and availability of the trialpartner /caregiver to provide and receive input by 
[CONTACT_100934] ( e.g.questions/instructions related to dosing information captured on dosing 
diary).
Every effort should be made to maintain the same trialpartner /caregiver for the duration of 
the study. However, if the trialpartner /caregiver is unable to continue with the study 
requirements, the trialpartner /caregiver should discuss with the site whether a suitable 
replacement can be found. If a new trialpartner /caregiver is identified, the new trial
partner /caregiver will need to sign the trial partner /caregiver informed consent.
8.10.2 Screening (Visit 1) 
Approximately [ADDRESS_111478] wash off their medications if 
considered medically appropriate (see Inclusion Criterion No. 1
0).If a participant has 
washed -off antipsychotic therapy (minimum [ADDRESS_111479]: MK-8189  68
PROTOCOL/AMENDMENT NO.: 017-04
MK-8189 -017-04FINAL PROTOCOL 21-JUL-2022
longer )during Screening, the NPI [INVESTIGATOR_100896], and will be 
considered the baseline value.
Participants may be rescreened after consultation with the Sponsor. Rescreening should 
include all screening procedures listed in the SoA, including consent review. Rescre en 
procedures cannot be conducted the day prior to intervention randomization if there are 
Baseline procedures planned per protocol.
Please see the operations manual for eCRF screening data entry requirements prior to 
randomization.
8.10.3 Baseline (Visit 2)
With in 3-[ADDRESS_111480] Baseline 
safety evaluations per Section 1.3 Schedule of Activities .
8.10.4 Intervention Period Visit (Visits 3 -9)
Day 1 (Visit 3)
Participants will return to the CRU on Day [ADDRESS_111481] administration of study intervention (Day 1). 
Outpatient CRU Visits (Visits 4 -9)
Partic ipants, not domiciled, will return for CRU v isitson Day 4, Day 7, Day 10 (Titration 3 
only) ,Day [ADDRESS_111482] 
dose.
Participant Daily Home & CRU Requirements
Participants will self -administer study intervention (Section 8.1.8) on days not required to be 
in the CRU.  Participants or trial partners/caregivers will record dosing date, time and 
number of tablets taken in a study intervention diary.
CRU staff will call the participants daily to check study intervention compliance, 
review/record AEs and if necessary, remind participants of next scheduled visit.
8.10.[ADDRESS_111483]: MK-8189  69
PROTOCOL/AMENDMENT NO.: 017-04
MK-8189 -017-04FINAL PROTOCOL 21-JUL-2022
of the investigator and with Sponsor agreement. The subset of study procedures completed 
will be communicated in a PCL.
8.10.6 Poststudy (Visit 10)
Participants will be required to return to clinic approximately [ADDRESS_111484] study clinic visit.
8.10.7 Study Design/Dosing/Procedures Modifications Permitted Within Protocol 
Parameters
See Section 6.6 for Dosing modifications permitted per pro tocol.
This is a Phase 1 assessment of MK- 8189 in humans, and the PK, pharmacodynamic, and 
safety profiles of the compound arestill being elucidated. This protocol is written with some 
flexibility to accommodate the inherent dynamic nature of Phase 1 clinical studies. 
Modifications to the dose, dosin g regimen, and/or clinical or laboratory procedures currently 
outlined may be required to achieve the scientific goals of the study objectives and/or to 
ensure appropriate safety monitoring of the study participants.
As such, some alterations from the curr ently outlined dose and/or dosing regimen may be 
permitted based on newly available data, but the maximum daily dose may not exceed those 
currently outlined in the protocol.
•Repeat of or decrease in the dose and/or titration steps of the study intervention
administere d.
•Decrease in the duration of study intervention administration ( e.g., number of days) .
•Addition of PK pause .
•Instructions to take study intervention with or without food or drink may also be modified 
based on newly available data .
•Modification of the PK sample processing and shippi[INVESTIGATOR_88647].
The PK sampling scheme currently outlined in the protocol may be modified during the study 
based on newly available PK or pharmacodynamic data ( e.g., to obtain data closer to the time 
of peak plasma concentrations). If indicated, these collected samples may also be assayed in 
an exploratory manner for metabolites and/or additional pharmacodynamic markers.
Up to an additional 50 mL of blood may be drawn for safety, PK, and/or pharmacodynamic 
analyses. The total blood volume withdrawn from any single participant will not exceed the 
maximum allowable volume during his/her participation in the entire study (Appendix 8).
08CG6Z
PRODUCT: MK-8189  70
PROTOCOL/AMENDMENT NO.: 017-04
MK-8189 -017-04FINAL PROTOCOL 21-JUL-2022
The timing of procedures for assessment of safety procedures ( e.g., vital signs, ECG, safety 
laboratory tests, etc .) may be modified during the study based on newly available data. 
Additional laboratory safety tests may be added to blood samples previously drawn to obtain 
additional safety information. These changes will not increase the number of study 
procedures for a given participant during his/her participation in the entire study.
It is understood that the current study may usesome or none of the alterations described 
above. Any alteration made to this protocol to meet the study objectives must be detailed by 
[CONTACT_21411] a letter to the Study File and forwarded to the investigator for retention. The 
letter may be forwarded to the IRB/IEC at the discretion of the investigator .
9 STATISTICAL ANALYSIS PLAN
9.1 Statistical Analysis Plan Summary
This section contains a brief summary of the statistical analyses for this trial. Full detail is in 
the Statistical Analysis Plan (SAP) (Section 9.2).
Safety:
For the primary objective, all AEs and AEs leading to discontinuation of study intervention
will be summarized and tabulated.
Summary statistics and plots will be generated for raw laboratory safety tests, 12-lead ECGs, 
and/or VS as well as for change from baseline, as deemed clinically appropriate.  Dependin g 
on the safety parameter, the difference from baseline will either be computed on the original 
scale (raw change from baseline) or on the log scale and back transformed for reporting 
(percent change from baseline). 
For exploratory objectives, s ummary st atistics and plots will be generated for Barnes 
Akathisia Rating Scale (BARS), Abnormal Involuntary Movement Scale (AIMS) and 
Simpson Angus Scale (SAS), as well as for change from baseline.  Responses to the C -SSRS 
will be listed. Additionally, summary sta tistics for change from baseline will be provided for 
MMSE -2, and NPI .
Pharmacokinetics : 
Descriptive summary statistics will also be provided for MK -[ADDRESS_111485]: MK-8189  71
PROTOCOL/AMENDMENT NO.: 017-04
MK-8189 -017-04FINAL PROTOCOL 21-JUL-2022
9.3 Hypotheses/Estimatio n
Objectives:
Refer to Section 3 for p rimary and exploratory objectives.
9.4 Analysis Endpoints
Safety: Primary safety endpoints will include all types of AEs and AEs leading to 
discontinuation of study intervention.
Additionally, for exploratory purposes ,labor atory safety tests, 12-lead ECGs, and VSwill be 
summarized. For laboratory safety tests, baseline is defined as readings obtained prior to first 
dose (Note: Readings from screening (Visit 1) will not serve as baseline for these 
parameters) .For 12-lead ECGs and VS, b aseline is defined as Day 1 predose reading s. 
Exploratory:
BARS, AIMS, and SAS for all participants. 
The Columbia Suicide Severity Rating Scale (C -SSRS) will be used to systematically and 
prospectively ascertain and document the oc currence of suicidal events (i.e., ideation and 
behavior). Responses on the C -SSRS are classified according to [ADDRESS_111486] severe treatment -emergent ideation and 
behavior event reported at a visit will be used for analysis and reporting. An event is 
considered treatment -emergent during the assessment phase if it newly emerged or is more 
severe compared to recent history (i.e., protocol- defined recent history prior to entering the 
trial as stated in the Inclusion/Exclusion criteria for suicidal ideation/behavior, up to and 
including the randomization visit). Readings from Day - 5 to Day -3 in Visit 2 will serve as 
baseline.
MMSE -2, and NPI [INVESTIGATOR_100897].  Readings from scre ening(Visit 1) will serve as 
baseline. (Note: For NPI, i f AP is washed off, the NPI [INVESTIGATOR_100898] .)
9.5 Analysis Populations
The following populations are defined for the analysis and reporting of data.  All participants
will be reported, and their data analyzed, according to the treatment(s) they actually received. 
All Participants as Treated (APasT): The All Participants as Treated Population consists of 
allparticipants who received at least one dose of treatment .  This population will be used for 
assessments of safety and tolerability.
Per-Protocol (PP) : The Per -Protocol Population consists of t he set of data generated by [CONTACT_3433] e 
subset of participants who comply with the protocol sufficiently to ensure that these data will
be likely to exhibit the effects of treatment, according to the underlying scientific model. 
Compliance covers such considerations as exposure to treatment, a vailability of 
08CG6Z
PRODUCT: MK-8189  72
PROTOCOL/AMENDMENT NO.: 017-04
MK-8189 -017-04FINAL PROTOCOL 21-JUL-2022
measurements and absence of important protocol deviations .  Important protocol deviations 
will be identified to the extent possible prior to unblinding by [CONTACT_100935]/compliance, and its analysis and interpretation.  Any participants or data values 
excluded from analysis will be identified, along with their reaso n for exclusion, in the CSR.  
At the end of the study, all participants who are compliant with the study procedure as 
aforementioned and have available data from at least one treatment (dose level) will be 
included in the Per -Protocol dataset. This populat ion will be used for the PK analysis.
9.6 Statistical Methods
Safety:
For primary objective, a ll AEs and AEs leading to discontinuation of study intervention will 
be summarized and tabulated. 
Summary statistics and plots will be generated for raw laboratory safety tests, 12-lead ECGs, 
and/or VS as well as for change from baseline, as deemed clinically appropriate.  Depending 
on the safety parameter, the difference from baseline will either be computed on the original 
scale (raw change from baseline) or on the log scale and back transformed for reporting 
(percent change from baseline). 
For exploratory purposes, summary statistics and plots will be generated for BARS, AIMS, 
SAS, as well as for change from baseline.  Responses to the C -SSRS will be listed.   
Additionally, s ummary statistics for change in MMSE-2 and NPI [INVESTIGATOR_100899].
Pharmacokinetics :   
Individual C24hrvalues will be listed, and the following (non -model -based) descriptive 
statistics will be provided: N (number of su bjects with non -missing data), arithmetic mean, 
standard deviation, arithmetic percent CV (calculated as [ADDRESS_111487] deviation/arithmetic 
mean), median, minimum, maximum, geometric mean, and geometric percent CV (calculated 
as 100 x sqrt(exp(s2) -1), w here s2is the observed variance on the natural log- scale).
The exploratory objective pertaining to the assessment of relationship between CYP2C9 
genetic polymorphs and the laboratory and PK of MK -8189, and the relationship between 
genetic variation and re sponse to the treatment may be addressed in a separate report .
9.7 Interim Analyses
During the in -life portion of the trial, descriptive summary level results (safety labs, VS, 
ECGs) will be prepared as needed to support decision- making meetings. No individual
participant level results will be provided. There are no planned interim analyses to test any 
formal hypotheses .
08CG6Z
PRODUCT: MK-8189  73
PROTOCOL/AMENDMENT NO.: 017-[ADDRESS_111488]: MK-8189  74
PROTOCOL/AMENDMENT NO.: 017-04
MK-8189 -017-04FINAL PROTOCOL 21-JUL-2022
10 SUPPORTING DOCUMENTATION AND OPERATIONAL 
CONSIDERATIONS
10.1 Appendix 1: Regulatory, Ethical, and Study Oversight Considerations
10.1.[ADDRESS_111489] for Clinical Trials
[COMPANY_006] Sharp &Dohme LLC, Rahway, NJ, [LOCATION_003] (MSD)
Code of Conduct for Interventional Clinical Trials
I. Introduction
A. Purpose
MSD, through its subsidiaries, conducts clinical trials worldwide to evaluate the safety and effectiveness of our 
products. As such, we are committed to des igning, implementing, conducting, analyzing, and reporting these trials 
in compliance with the highest ethical and scientific standards. Protection of participants in clinical trials is the 
overriding concern in the design and conduct of clinical trials. I n all cases, MSD clinical trials will be conducted 
in compliance with local and/or national regulations (including all applicable data protection laws and
regulations), and International Council for Harmonisation Good Clinical Practice (ICH- GCP), and also in 
accordance with the ethical principles that have their origin in the Declaration of Helsinki.
B. Scope
Highest ethical and scientific standards shall be endorsed for all clinical interventional investigations sponsored by 
[CONTACT_19481] ( parties) employed for their execution (e.g., contract research organizations, 
collaborative research efforts). This Code is not intended to apply to trials that are observational in nature, or 
which are retrospective. Further, this Code does not apply to i nvestigator -initiated trials, which are not under the 
full control of MSD.
II. Scientific Issues
A. Trial Conduct
1. Trial Design
Except for pi[INVESTIGATOR_19354], clinical trial protocols will be hypothesis -driven to assess safety, efficacy 
and/or pharmacokinetic or pharmacodynamic indices of MSD or comparator products. Alternatively, MSD 
may conduct outcomes research trials, trials to assess or validate various endpoint measures, or trials to 
determine patient preferences, etc.
The design (i.e., participant population, duration, statistical power) must be adequate to address the specific 
purpose of the trial and shall respect the data protection rights of all participants, trial site staff and, where 
applicable, third parties . All trial proto cols are and will be assessed for the need and capability to enroll 
underrepresented groups. Participants must meet protocol entry criteria to be enrolled in the trial. 
2. Site Selection
MSD ’s clinical trials are conducted globally in many different count ries and in diverse populations, including 
people of varying age, race, ethnicity, gender, and accounting for other potential disease related factors. MSD 
selects investigative sites based on medical expert[INVESTIGATOR_18700], access to appropriate participants, adequacy of facilities 
and staff, previous performance in clinical trials, as well as budgetary considerations. Prior to trial initiation, 
sites are evaluated by [CONTACT_26397] (or individuals acting on behalf of MSD) to assess the ability to 
successfully conduct th e trial.
08CG6Z
PRODUCT: MK-8189  75
PROTOCOL/AMENDMENT NO.: 017-04
MK-8189 -017-04FINAL PROTOCOL 21-JUL-2022
Where appropriate, and in accordance with regulatory authority guidance, MSD will make concerted efforts 
to raise awareness of clinical trial opportunities in various communities. MSD will seek to engage 
underrepresented groups and those dispropor tionately impacted by [CONTACT_26398]. MSD will support 
clinical trial investigators to enroll underrepresented groups and expand access to those who will ultimately 
use the products under investigation.
3. Site Monitoring/Scientific Integrity
Investigative trial sites are monitored to assess compliance with the trial protocol and Good Clinical Practice 
(GCP). MSD reviews clinical data for accuracy, completeness, and consistency. Data are verified versus 
source documentation according to standard operating procedures. Per MSD policies and procedures, if
potential fraud, scientific/research misconduct, privacy incidents/breaches orClinical Trial -related 
Significant Quality Issues are reported, such matters are investigated . When necessary, appropriat e corrective 
and/or preventative actions are defined and regulatory authorities and /orethics review committees are 
notified.
B. Publication and Authorship
Regardless of trial outcome, MSD commits to publish the primary and secondary results of its registe red trials of 
marketed products in which treatment is assigned, according to the pre -specified plans for data analysis. To the 
extent scientifically appropriate, MSD seeks to publish the results of other analyses it conducts that are important 
to patients, physicians, and payers. Some early phase or pi[INVESTIGATOR_26346] -generating rather 
than hypothesis testing; in such cases, publication of results may not be appropriate since the trial may be 
underpowered and the analyses complicated by [CONTACT_19482].
MSD’s policy on authorship is consistent with the recommendations published by [CONTACT_26399] (ICMJE). In summary, authorship should reflect significant contribution to th e design and 
conduct of the trial, performance or interpretation of the analysis, and/or writing of the manuscript. All named 
authors must be able to defend the trial results and conclusions. MSD funding of a trial will be acknowledged in 
publications.
III. Participant Protection
A. Regulatory Authority and Ethics Committee Review (Institutional Review Board [IRB]/Independent Ethics 
Committee [IEC])
All protocols and protocol amendments will be submitted by [CONTACT_88708]/authorization prior to implementation of the trial or amendment, in compliance with local and/or 
national regulations.
The protocol, protocol amendment(s), informed consent form, investigator’s brochure, and other relevant trial 
documents must b e reviewed and approved by [CONTACT_2717]/IEC before being implemented at each site, in compliance 
with local and/or national regulations. Changes to the protocol that are required urgently to eliminate an 
immediate hazard and to protect participant safety may be enacted in anticipation of ethics committee approval. 
MSD will inform regulatory authorities of such new measures to protect participant safety, in compliance with 
local and/or national regulations.
B. Safety
The guiding principle in decision -making in cli nical trials is that participant welfare is of primary importance. 
Potential participants will be informed of the risks and benefits of, as well as alternatives to, trial participation. At 
a minimum, trial designs will take into account the local standard of care.
All participation in MSD clinical trials is voluntary. Participants enter the trial only after informed consent is 
obtained. Participants may withdraw from an MSD trial at any time, without any influence on their access to, or 
receipt of, medical care that may otherwise be available to them.
08CG6Z
PRODUCT: MK-8189  76
PROTOCOL/AMENDMENT NO.: 017-[ADDRESS_111490] extent possible , as well as all 
applicable data protection rights . Unless required by [CONTACT_2371], only the investigator, Sponsor (or individuals acting on 
behalf of MSD), ethics committee, and/or regulatory authorities will have access to confidential medical records 
that might identify the participant by [CONTACT_2300].
D. Genomic Research
Genomic research will only be conducted in accordance with a protocol and informed consent authorized by [CONTACT_88709].
IV. Financial Considerations
A. Payments to Investigators
Clinical trials are time -and labor -intensive. It is MSD’s policy to compensate investigators (or the sponsoring 
institution) in a fair manner for the work performed in support of MSD trials. MSD does not pay incentives to 
enroll participants in its trials. However, when enrollment is particularly challenging, additional payments may be 
made to compensate for the time spent in extra recruiting efforts.
MSD does not pay for participant referrals. However, MSD may compensate referring physicians for time spent 
on chart review and medical evaluation to identify potentially eligible participants.
B. Clinical Re search Funding
Informed consent forms will disclose that the trial is sponsored by [CONTACT_19487], and that the investigator or sponsoring 
institution is being paid or provided a grant for performing the trial. However, the local ethics committee may 
wish to alter th e wording of the disclosure statement to be consistent with financial practices at that institution. As 
noted above, all publications resulting from MSD trials will indicate MSD as a source of funding.
C. Funding for Travel and Other Requests
Funding of tr avel by [CONTACT_19488] (e.g., to scientific meetings, investigator meetings, etc.) will be 
consistent with local guidelines and practices.
V. Investigator Commitment
Investigators will be expected to review MSD’s Code of Conduct as an appe ndix to the trial protocol, and in signing the 
protocol, agree to support these ethical and scientific standards.
10.1.2 Financial Disclosure
Financial d isclosure requirements are outlined in the US Food and Drug Administration 
Regulations, Financial Disclosure by [CONTACT_6230] (21 CFR Part 54). It is the 
Sponsor ’s responsibility to determine, based on these regulations, whether a request for 
financial d isclosure information is required. It is the investigator ’s/subinvestigator ’s 
responsibility to comply with any such request.
The investigator/subinvestigator(s) agree, if requested by [CONTACT_19489] 21 
CFR Part 54, to provide his/her financial interests in and/or arrangements with the Sponsor to 
allow for the submission of complete and accu rate certification and disclosure statements. 
The investigator/subinvestigator(s) further agree to provide this information on a 
Certification/Disclosure Form, frequent ly known as a financial disclosure form, provided by 
[CONTACT_1034]. The investigator/subin vestigator(s) also consent to the transmission of this 
08CG6Z
PRODUCT: MK-8189  77
PROTOCOL/AMENDMENT NO.: 017-[ADDRESS_111491] this study in compliance with all applicable data protection 
regulations.
Participants will be assigned a unique identifier by [CONTACT_1034]. Any participant records or 
datasets that are transferred to the Sponsor will con tain the identifier only; participant names 
or any information that would make the participant identifiable will not be transferred.
The participant must be informed that his/her personal study -related data will be used by [CONTACT_19490]. The level of disclosure must also be 
explained to the participant. 
The participant must be informed that his/her medical records may be examined by [CONTACT_100936], by 
[CONTACT_6667]/IEC members, and by [CONTACT_6668].
[IP_ADDRESS] Confidentiality of Data
By [CONTACT_12570], the investigator affirms to the Sponsor that information furnished to 
the investigator by [CONTACT_19492], and such information will 
be divulged to the IRB , IEC ,or similar or expert committee; affiliated institution and 
employees, only under an appropriate understanding of confidentiality with such board or 
committee, affiliated institution and employees. Data generated by [CONTACT_19493], except to the extent that it is included in a 
publication as provided in the Publications section of this protocol.
[IP_ADDRESS] Confidentiality of Participant Records
By [CONTACT_12570], the investigator agrees that the Sponsor (or Sponsor representative), 
IRB/IEC, or regulatory authority representatives may consult and/or copy study documents to 
verify worksheet/ CRF data. By [CONTACT_17317], the participant agrees to this 
process. If study documents will be photocopi[INVESTIGATOR_88648]/ CRF information, the participant will be identified by [CONTACT_19494]; full 
names/initials will be masked before transmission to the Spon sor.
By [CONTACT_12570], the investigator agrees to treat all participant data used and 
disclosed in connection with this study in accordance with all applicable privacy laws, rules 
and regulations.
[IP_ADDRESS] Confidentiality of IRB/IEC Information
The Sponsor is required to record the name [CONTACT_19525]/IEC that reviews and 
approves this study. The Sponsor is also required to document that each IRB/IEC meets 
regulatory and ICH GCP requirements by [CONTACT_88711] 
08CG6Z
PRODUCT: MK-8189  78
PROTOCOL/AMENDMENT NO.: 017-04
MK-8189 -017-04FINAL PROTOCOL 21-JUL-2022
and qua lifications of the IRB/IEC members and to make these records available for 
regulatory agency review upon request by [CONTACT_19496] .
10.1.[ADDRESS_111492] 
proprietary inform ation and to provide comments.
Authorship will be determined by [CONTACT_11403] I CMJE authorship 
requirement s.
10.1.5 Compliance with Study Registration and Results Posting Requirements
Under the terms of the FDAAA of 2007 and t he EMA clinical trial Directive 2001/20/EC, the 
Sponsor of the study is solely responsible for determining whether the study and its results 
are subject to the requirements for submission to http://www.clinicaltrials.gov, 
www.clinicaltrialsregister.eu or other local registries. MSD, as Sponsor of this study, will 
review this protocol and submit the information necessary to fulfill these requirements. MSD 
entries are not limited to FDAAA or the EMA clinical trials directive mandated trials . 
Information posted will allow participants to identify potentially appropriate studies for their 
disease conditions and pursue participation by [CONTACT_3379] a central contact [CONTACT_88712] -site contact i nformation.
By [CONTACT_12570], the investigator acknowledges that the statutory obligations under 
FDAAA, the EMA clinical trials directive ,or other locally mandated registries are that of the 
Sponsor and agrees not to submit any information about t his study or i ts results to those 
registries.
10.1.[ADDRESS_111493] the study in an efficient and 
diligent manner and in conformance with this protocol; generally accepted sta ndards of G CP
(eg, I CH GCP: Consolidated Guideline and other generally accepted standards of GCP ); and 
all applicable federal, state and local laws, rules and regulations relating to the conduct of the 
clinical study.
The Code of Conduct, a collection of g oals and considerations that govern the ethical and 
scientific conduct of clinical investigations sponsored by [CONTACT_19487], is provided i n this appendix 
under the Code of Conduct for Clinical Trials.
08CG6Z
PRODUCT: MK-8189  79
PROTOCOL/AMENDMENT NO.: 017-04
MK-8189 -017-04FINAL PROTOCOL 21-JUL-2022
The investigator agrees not to seek reimbursement from participants, their insurance 
providers, or from government programs for procedures included as part of the study 
reimbursed to the investigator by [CONTACT_1034].
The investigator will promptly inform the Sponsor of any regulatory authority inspection 
conducted for this study.
The investigator agrees to provide the Sponsor with relevant information from inspection 
observations/findings to allow the Sponsor to assist in responding to any citations resulting 
from regulatory authority inspection and will provide the Sponsor with a copy of the 
proposed response for consultation before submission to the regulatory authority. 
Persons debarred from conducting or working on clinical studies by [CONTACT_19500]’s studies. The investigator 
will immediately disclose in writing to the Sponsor if any person who is involved in 
conducting the study is debarred or if any proceeding for debarment is pending or, to the best 
of the investigator’s knowledge, threatened .
10.1.7 Data Quality Assurance
All participant data relating to the study will be recorded on printed or electronic CRF unless 
transmitted to the Sponsor or designee electronically (eg, laboratory data). The investigator 
or qualified d esignee is responsible for verifying that data entries are accurate and correct by 
[CONTACT_1189].
Detailed information regarding Data Management procedures for this protocol will be 
provided separately.
The investigator must maintain accurate documentation (source data) that supports the 
information entered in the CRF.
The investigator must permit study- related monitoring, audits, IRB/IEC review, and 
regulatory agency inspections and provide direct access to source data docume nts.
Study documentation will be promptly and fully disclosed to the Sponsor by [CONTACT_63551], 
copying, review, and audit at reasonable times by [CONTACT_19502]. The investigator agrees to promptly take any reasonable steps that are 
requested by [CONTACT_88713] a result of an audit or inspection to 
cure deficiencies in the study documentation and worksheets/CRFs .
The Sponsor or designee is responsible for the data management of this study including 
quality checking of the data.
Study monitors will perform ongoing source data review and verification to confirm that data 
entered into the CRF by [CONTACT_1191], complete, and verifiable from 
source documents; that the safety and rights of participants are being protected; and that the 
08CG6Z
PRODUCT: MK-8189  80
PROTOCOL/AMENDMENT NO.: 017-04
MK-8189 -017-04FINAL PROTOCOL 21-JUL-2022
study is being conducted in accordance with the currently approved protocol and any other 
study agreements, ICH GCP, and all applicable regulatory requirements.
Records and documents, including participants’ documented informed consent , pertaining to 
the conduct of this study must be retained by [CONTACT_1732] 15 years after study 
complet ion unless local regulations or institutional policies require a longer retention period. 
No records may be destroyed during the retention period without the written approval of the 
Sponsor. No records may be transferred to another location or party withou t written 
notification to the Sponsor .
10.1.8 Source Documents
Source documents provide evidence for the existence of the participant and substantiate the 
integrity of the data collected. The investigator/institution should maintain adequate and 
accurate source documents and study records that include al lpertinent observations on each 
of the site’s participants. Source documents and data should be attributable, legible, 
contemporaneous, original, accurate, and complete. Changes to source data should be 
traceable, should not obscure the original entry, and should be explained if necessary (eg, via 
an audit trail). Source documents are filed at the investigator’s site.
Data reported on the CRF or entered in the eCRF that are transcribed from source documents 
must be consistent with the source documents or the discrepancies must be explained. The 
investigator /institution may need to request previous medical records or transfer records, 
depending on the study. Also, current medical records must be available .
10.1.[ADDRESS_111494] udy or study -site participation in the study for 
medical, safety, regulatory, administrative, or other reasons consistent with applicable laws, 
regulations, and GCP.
In the event the Sponsor prematurely terminates a particular study site, the Sponsor or 
designee will promptly notify that study site’s IRB/IEC as specified by [CONTACT_88714](s).
08CG6Z
PRODUCT: MK-8189  81
PROTOCOL/AMENDMENT NO.: 017-04
MK-8189 -017-04FINAL PROTOCOL 21-JUL-2022
10.2 Appendix 2: Clinical Laboratory Tests
•The tests detailed in Table 4will be performed by [CONTACT_2237].
Exception: Routine urinalysis and urine pregnancy tests will be done locally at the site. A
urinalysis sample will only be sent to the central lab if microscopic examination is 
required, i.e. blood or protein is abnormal. 
•Local laboratory results are only required in the event that the central laboratory results 
are not available in time for eit her study intervention administration and/or response 
evaluation. If a local sample is required, it is important that the sample for central 
analysis is obtained at the same time. Additionally, if the local laboratory results are used 
to make either a study intervention decision or response evaluation, the results must be 
entered into the CRF.
•Protocol -specific requirements for inclusion or exclusion of participants are detailed in 
Section 5 of the protocol.
•Additional tests may be performed at any time dur ing the study as determined necessary 
by [CONTACT_11006].
Table 4 Protocol -require d Safety Laboratory Assessments
Laboratory 
Assessments Parameters
Hematology Platelet Count RBC Indices:
MCV
MCH
ReticulocytesWBC count with 
Differential:
Neutrophils
Lymphocytes
Monocytes
Eosinophils
BasophilsRBC Count
Hemoglobin
Hematocrit
Chemistry BUN Potassium AST/SGOT Total bilirubin (and 
direct bilirubin, if 
total bilirubin is 
above the ULN)
Albumin Bicarbonate or 
Total CO 2Chloride Phosphorous
Creatinine Sodium ALT/SGPT Total Protein
Glucose (fasting) Calcium Alkaline 
phosphatase
Routine 
Urinalysis•Specific gravity
•pH, glucose, protein, blood, ketones, [bilirubin, urobilinogen, nitrite, leukocyte 
esterase] by [CONTACT_5230]
•Microscopic examination (if blood or protein is abnormal)
08CG6Z
PRODUCT: MK-8189  82
PROTOCOL/AMENDMENT NO.: 017-04
MK-8189 -017-04FINAL PROTOCOL 21-JUL-2022
Laboratory 
Assessments Parameters
Pregnancy 
Testing•Highly sensitive serum or urine hCG pregnancy test (as needed for WOCBP)
Other Screening 
Tests•FSH (as needed in WONCBP only)
• U rine alcohol and drug screen (to include at minimum: amphetamines, barbiturates, 
cocaine, opi[INVESTIGATOR_858], cannabinoids and benzodiazepi[INVESTIGATOR_1651] )
•Serology (HIV antibody, HBsAg, and hepatitis C virus antibody )
•All study -required laboratory assessments will be performed by a central laboratory .
ALT=alanine aminotransferase ;AST=aspartate aminotransferase ;BUN=blood urea nitrogen ;FSH=follicle -stimulating 
hormone ; [HBsAg=hepatitis B surface antigen]; hCG=human chorionic gonadotropin ; [HIV=human immunodeficiency 
virus]; MCH=mean corpuscular hemoglobin ; MCV=mean corpuscular volume ;RBC=red blood c ell;SGOT=serum 
glutamic -oxaloacetic transaminase ; SGPT=serum glutamic -pyruvic transaminase ;ULN=upper limit of normal ; 
WBC=white blood cell; WOCBP=women of childbearing potential; WONCBP=women of nonchildbearing potentia l
The i nvestigator (or medically qualified designee) must document their review of each 
laboratory safety report.
08CG6Z
PRODUCT: MK-8189  83
PROTOCOL/AMENDMENT NO.: 017-04
MK-8189 -017-04FINAL PROTOCOL 21-JUL-2022
10.3 Appendix 3: Adverse Events: Definitions and Procedures for Recording, 
Evaluating, Follow -up, and Reporting
10.3.1 Definition of AE
AE definition
•An AE is any untoward medical occurrence in a clinical study participa nt, temporally 
associated with the use of study intervention, whether or not considered related to the 
study intervention.
•Note: An AE can therefore be any unfavorable and unintended sign (including an 
abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally 
associated with the use of a study intervention.
•Note: For purposes of AE definition, study intervention (also referred to as Sponsor’s 
product) includes any pharmaceutical product, biological product, vaccine, diagnostic 
agent, medical device, combination product, or protocol specified procedure whether 
investigational or marketed (including placebo, active comparator product, or run -in 
intervention) , manufactured by, licensed by, provided by, or distributed by [CONTACT_88715].
Events meeting the AE definition
•Any abnormal laboratory test results (hematology, clinical chemistry, or urinalysis) or 
other saf ety assessments (eg, ECG, radiological scans, vital signs measurements), 
including those that worsen from baseline, considered clinically significant in the medical 
and scientific judgment of the investigator.
•Exacerbation of a chronic or intermittent pree xisting condition including either an 
increase in frequency and/or intensity of the condition.
•New conditions detected or diagnosed after study intervention administration even 
though it may have been present before the start of the study.
•Signs, symptoms, or the clinical sequelae of a suspected drug -drug interaction.
•Signs, symptoms, or the clinical sequelae of a suspected overdose of either study 
intervention or a concomitant medication.
•For all reports of overdose (whether accidental or intentional) with an associated AE, the 
AE term should reflect the clinical symptoms or abnormal test result. An overdose 
without any associated clinical symptoms or abnormal laboratory results is reported using 
the terminology “accidental or intentional overdose without a dverse effect.”
•Any new cancer or progression of existing cancer.
08CG6Z
PRODUCT: MK-8189  84
PROTOCOL/AMENDMENT NO.: 017-04
MK-8189 -017-04FINAL PROTOCOL 21-JUL-2022
Events NOT meeting the AE d efinition
•Medical or surgical procedure (eg, endoscopy, appendectomy): the condition that leads to 
the procedure is the AE.
•Situations in which an untoward medical occurrence did not occur (social and/or 
convenience admission to a hospi[INVESTIGATOR_307]).
•Anticipated day -to-day fluctuations of preexisting disease(s) or condition(s) present or 
detected at the start of the study that do not worsen.
•Surgical procedure(s) planned prior to informed consent to treat a preexisting condition 
that has not worsened.
•Refe r to Section 8.4.[ADDRESS_111495] medical occurrence that, at any dose:
a.Results in death
b.Is life -threatening
•The term “ life-threatening ”in the definition of “serious” refers to an event in which 
the participant was at risk of death at the time of the event. It does not refer to an 
event, which hypothetically might have caused death, if it were more severe.
c.Requires inpatient hospi[INVESTIGATOR_1081]
•Hospi[INVESTIGATOR_19357], regardless of length of stay, even 
if the hospi[INVESTIGATOR_2138] a precautionary measure for continued observation. (Note: 
Hospi[INVESTIGATOR_19358] a preexisting condition that has not 
worsened is not an SAE. )A preexisting condition is a clinical condition that is 
diagnosed prior to the use of an MSD product and is documented in the participant’s 
medical history.
d.Results in persistent or significant disability/incapacity
•The term disability means a substantial disruption of a person’s ability to conduct 
normal life functions.
•This definition is not intended to include experiences of relatively minor medical 
significance such as uncomplicated headache, nausea, vomiting, diarrhea, influenza, 
08CG6Z
PRODUCT: MK-8189  85
PROTOCOL/AMENDMENT NO.: 017-04
MK-8189 -017-04FINAL PROTOCOL 21-JUL-2022
and accidental trauma (eg, sprained ankle) that may interfere with or prevent 
everyday life functions but do not constitute a substantial disruption.
e.Is a congenital anomaly/birth defect
•In offspring of participant taking the product regardless of time to diagnosis.
f.Other important medical events
•Medical or scientific judgment should be exercised in deciding whether SAE 
reporting is appropriate in other situations such as important medical events that may 
not be immediately life -threatening or result in death or hospi[INVESTIGATOR_100900] 1 
of the other outcomes listed in the above definition. These events should usually be 
considered serious.
•Examples of such events include invasive or malignant cancers, intensive treatment in 
an emergency room or at home for allergic bronchospasm, blood dyscrasias or 
convulsions that do not result in hospi[INVESTIGATOR_059], or development of drug dependency 
or drug abuse.
10.3.3 Additional Events Reported
Additional events that require r eporting
In addition to the above criteria, AEs meeting either of the below criteria, although not 
serious per ICH definition, are reportable to the Sponsor.
•Is a cancer
•Is associated with an overdose
10.3.4 Recording AE and SAE
AE and SAE r ecording
•When an AE/SAE occurs, it is the responsibility of the investigator to review all 
documentation (eg, hospi[INVESTIGATOR_1088], laboratory, and diagnostics reports) related to 
the event.
•The investigator will record all relevant AE/SAE information on the AE 
CRF s/worksheets at each examination.
•It is not acceptable for the investigator to send photocopi[INVESTIGATOR_10914]’s medical 
records to the Sponsor in lieu of completion of the AE CRF page.
•There may be instances when copi[INVESTIGATOR_100901] n cases are requested by 
[CONTACT_1034]. In this case, all participant identifiers, with the exception of the participant 
08CG6Z
PRODUCT: MK-8189  86
PROTOCOL/AMENDMENT NO.: 017-04
MK-8189 -017-04FINAL PROTOCOL 21-JUL-2022
number, will be blinded on the copi[INVESTIGATOR_19361].
•The investigator will attempt to establis h a diagnosis of the event based on signs, 
symptoms, and/or other clinical information. In such cases, the diagnosis (not the 
individual signs/symptoms) will be documented as the AE/SAE.
Assessment of i ntensity
•An event is defined as “serious” when it mee ts at least 1 of the predefined outcomes as 
described in the definition of an SAE, not when it is rated as severe.
•The investigator will make an assessment of intensity for each AE and SAE (and other 
reportable safety event) reported during the study and a ssign it to 1 of the following
categories:
-Mild: An event that is easily tolerated by [CONTACT_2299], causing minimal discomfort, 
and not interfering with everyday activities (for pediatric studies, awareness of 
symptoms, but easily tolerated).
-Moderate: An event that causes sufficient discomfort to interfere with normal 
everyday activities (for pediatric studies, definitely acting like something is wrong).
-Severe: An event that prevents normal everyday activities. An AE that is assessed as 
severe should n ot be confused with an SAE. Severe is a category used for rating the 
intensity of an event; and both AE and SAE can be assessed as severe (for pediatric 
studies, extremely distressed or unable to do usual activities).
Assessment of c ausality
•Did the Sponsor ’s product cause the AE?
•The determination of the likelihood that the Sponsor ’s product caused the AE will be 
provided by [CONTACT_19427] a qualified physician. The investigator’s signed/dated 
initials on the source document or worksheet that supports the causality noted on the AE 
form, ensures that a medically qualified assessment of causality was done . This initialed 
document must be retained for the required regulatory time frame. The criteria below are 
intended as reference guidelines to a ssist the investigator in assessing the likelihood of a 
relationship between the test product and the AE based upon the available information.
•The following components are to be used to assess the relationship between the 
Sponsor ’s product and the AE ; the greater the correlation with the components and 
their respective elements (in number and/or intensity), the more likely the Sponsor ’s 
product caused the AE:
-Exposure: Is there evidence that the participant was actually exposed to the 
Sponsor ’s product such as: reliable history, acceptable compliance assessment (pi[INVESTIGATOR_4382] 
08CG6Z
PRODUCT: MK-8189  87
PROTOCOL/AMENDMENT NO.: 017-04
MK-8189 -017-04FINAL PROTOCOL 21-JUL-2022
count, diary, etc), expected pharmacologic effect, or measurement of 
drug/metabolite in bodily specimen?
-Time Course: Did the AE follow in a reasonable temporal sequence from 
administration of t he Sponsor ’s product? Is the time of onset of the AE compatible 
with a drug -induced effect (applies to studies with investigational medicinal 
product)?
-Likely Cause: Is the AE not reasonably explained by [CONTACT_19511], other drug(s)/vaccine(s), or other host or environmental factors.
-Dechallenge: Was the Sponsor ’s product discontinued or dose/exposure/frequency 
reduced?
◦If yes, did the AE resolve or improve?
◦If yes, this is a positive dechallenge.
◦If no, this is a negative dechallenge.
(Note: This criterion is not applicable if: (1) the AE resulted in death or permanent 
disability; (2) the AE resolved/improved despi[INVESTIGATOR_100902] S ponsor ’s 
product; (3) the study is a single -dose drug study; or (4) Sponsor ’s product(s) is/are 
only used 1 time.)
-Rechallenge: Was the participant re -exposed to the Sponsor ’s product in this study?
◦If yes, did the AE recur or worsen?
◦If yes, this is a positive rechallenge.
◦If no, this is a negative rechallenge.
(Note: This criterion is not applicable if: (1) the initial AE resulted in death or 
permanent disability, or (2) the study is a single -dose drug study; or (3) Sponsor ’s 
product(s) is/are used only 1 time.)
NOTE: IF A RECHALLENGE IS PLANNED FOR AN AE THAT WAS SERIOUS AND 
MAY HAVE BEEN CAUSED BY [CONTACT_26370] ’S PRODUCT, OR IF RE -EXPOSURE 
TO THE SPONSOR ’S PRODUCT POSES ADDITIONAL POTENTIAL SIGNIFICANT 
RISK TO THE PARTICIPANT THEN THE RECHALLENGE MUST BE A PPROVED IN 
ADVANCE BY [CONTACT_93333], AND IF REQUIRED, THE 
IRB/IEC .
•Consistency with study intervention profile: Is the clinical/pathological presentation of 
the AE consistent with previous knowledge regarding the Sponsor ’s product or drug class 
pharmacology or toxicology?
08CG6Z
PRODUCT: MK-8189  88
PROTOCOL/AMENDMENT NO.: 017-04
MK-8189 -017-04FINAL PROTOCOL 21-JUL-2022
•The assessment of relationship will be reported on the CRFs /worksheets by [CONTACT_26368] a qualified physician according to their best clinical judgment, 
including consideration of the above elements.
•Use the following scale of criteria as guidance (not all criteria must be present to be 
indicative of a Sponsor ’s product relationship).
-Yes, there is a reasonable possibility of Sponso r’s product relationship:
◦There is evidence of exposure to the Sponsor ’s produc t. The temporal sequence 
of the AE onset relative to the administration of the Sponsor ’s product is 
reasonable. The AE is more likely explained by [CONTACT_1034] ’s product than by 
[CONTACT_5748].
-No, there is not a re asonable possibility of Sponsor’ s product r elationship:
◦Participant did not receive the Sponsor ’s product OR temporal sequence of the 
AE onset relative to administration of the Sponsor ’s product is not reasonable 
OR the AE is more likely explained by [CONTACT_26372]’s 
product. (Also entered for a participant with overdose without an associated 
AE.)
•The investigator must review and provide an assessment of causality for each AE/SAE 
and document this in the medical notes .
•There may be situations in which an SAE has occurred and the investigator has minimal 
information to include in the initial report to the Sponsor. However, it is very important 
that the investigator always make an assessment of causality for every event before the 
initial transmission of the SAE data to the Sponsor.
•The investigator may change their opi[INVESTIGATOR_9242] -up information 
and send an SAE follow- up report with the updated causality assessment.
•The causality assessment is 1 of the criteria used when determining regulatory reporting 
requi rements.
Follow -up of AE and SAE
•The investigator is obligated to perform or arrange for the conduct of supplemental 
measurements and/or evaluations as medically indicated or as requested by [CONTACT_19514]/or causality of the AE or SAE as fully as possible. This may 
include additional laboratory tests or investigations, histopathological examinations, or 
consultation with other health care professionals.
•New or updated information will be recorded in the CRF.
•The investigator will submit any updated SAE data to the Sponsor within [ADDRESS_111496]: MK-8189  89
PROTOCOL/AMENDMENT NO.: 017-04
MK-8189 -017-04FINAL PROTOCOL 21-JUL-2022
10.3.5 Reporting of AE s, SAE s, and Other Reportable Safety Events to the Sponsor
AE, SAE, and o ther reportable safety event reporting to Sponsor via electronic d ata 
collection t ool
•The primary mechanism for reporting to the Sponsor will be the EDC tool.
-Electronic reporting procedures can be found in the EDC data entry guidelines (or 
equivalent).
-If the electronic system is unavailable for more than 24 hours, then the site will use 
the paper AE Reporting form.
◦Reference Section 8.4.1 for reporting time requirements.
•The site will enter the SAE data into the electronic system as soon as it becomes 
available.
•After the study is completed at a given site, the EDC tool will be taken off -line to prevent 
the entry of new data or changes to existing data.
•If a site receives a report of a new SAE from a study participant or receives updated data 
on a previously reported SAE after the EDC tool has been taken off -line, then the si te can 
report this information on a paper SAE form or by [CONTACT_756] (see next section).
•Contacts for SAE reporting can be found in the Investigator Study File Binder (or 
equivalent).
SAE reporting to the Sponsor via paper CRF
•If the EDC tool is not operational, facsimile transmission or secure e -mail of the SAE 
paper CRF is the preferred method to transmit this information to the Sponsor.
•In rare circumstances and in the absence of facsimile equipment, notification by 
[CONTACT_9337] a copy of t he SAE data collection tool sent by [CONTACT_19515].
•Initial notification via telephone does not replace the need for the investigator to 
complete and sign the SAE CRF pages within the designated reporting time frames.
•Contacts and instructions for SAE reporting and paper reporting procedures can be found 
in the Investigator Study File Binder (or equivalent) .
08CG6Z
PRODUCT: MK-8189  90
PROTOCOL/AMENDMENT NO.: 017-04
MK-8189 -017-04FINAL PROTOCOL 21-JUL-2022
10.4 Appendix 4: Medical Device and Drug- device Combination Products : Product 
Quality Complaints/Malfunction s: Definition s, Recordi ng, and Follow -up
Not Applicable
08CG6Z
PRODUCT: MK-8189  91
PROTOCOL/AMENDMENT NO.: 017-04
MK-8189 -017-04FINAL PROTOCOL 21-JUL-2022
10.5 Appendix 5: Contraceptiv e Guidance
10.5.1 Definitions
Women of Childbearing Potential (WOCBP)
A woman is considered fertile following menarche and until becoming postmenopausal 
unless permanently sterile (see below):
If fertility is unclear (eg, amenorrhea in adolescents or athletes) and a menstrual cycle cannot 
be confirmed before first dose of study intervention, additional evaluation should be 
considered.
Women in the following categories are not considered WOCBP:
•Premenarchal
•Premenopausal female with 1 of the following:
-Documented hysterectomy
-Documented bilateral salpi[INVESTIGATOR_1656]
-Documented bilateral oophorectomy
For individuals with permanent infertility due to an alternate medical cause other than the 
above (eg, Mullerian agenesis, androgen insensitivity), investigator discretion should be 
applied to determining study entry.
Note: Documentation can come from the site personnel’s revi ew of the participant’s medical 
records, medical examination, or medical history interview.
•Postmenopausal female
-A postmenopausal state is defined as no menses for 12 months without an alternative 
medical cause.
◦A high FSH level in the postmenopausal range may be used to confirm a 
postmenopausal state in women not using hormonal contraception or HRT. 
However, in the absence of [ADDRESS_111497]: MK-8189  92
PROTOCOL/AMENDMENT NO.: 017-[ADDRESS_111498] Low User Dependencyb
Failure rate of <1% per year when used consistently and correctl y.
•Progestogen -only contraceptive implantc,d
•IUSc,e
•Non-hormonal IUD
•Bilateral tubal occlusion
•Azoospermic partner (vasectomized or secondary to medical cause)
This is a highly effective contraception method provided that the partner is the sole male sexual partner of 
the WOCBP and the absence of sperm has bee n confirmed. If not, an additional highly effective method of 
contraception should be used. A spermatogenesis cycle is approximately 90 days.
Note: Documentation of azoospermia for a male participant can come from the site personnel’s review of 
the partic ipant’s medical records, medical examination, or medical history interview.
Highly Effective Contraceptive Methods That Are User Dependentb
Failure rate of <1% per year when used consistently and correctly.
•Combined (estrogen -and progestogen -containing ) hormonal contraceptionc,d
-Oral
-Intravaginal
-Transdermal
-Injectable
•Progestogen -only hormonal contraceptionc,d
-Oral
-Injectable
Sexual Abstinence
•Sexual abstinence is considered a highly effective method only if defined as refraining from heterosexual 
intercourse during the entire period of risk associated with the study intervention. The reliability of sexual 
abstinence needs to be evaluated in relation to the duration of the study and the preferred and usual lifestyle 
of the participant.
Methods That Are Not Considered Highly Effective
Failure rate of >1% per year when used consistently and correctly.
•Progesterone- only hormonal contraception where inhibition of ovulation is not the primary mode of action
•Male or female condom with or without spermicide
•Cervical cap, diaphragm, or sponge with spermicide
•A combination of male condom with either cervical cap, diaphragm, or sponge with spermicide (double 
barrier methods) .
a   Contraceptive use by [CONTACT_93335].
b   Typi[INVESTIGATOR_63485] -use failure rates (ie, when used consistently and correctly).
[If hormonal contraceptio n efficacy for a female participant is potentially decreased due to interaction(s) with study 
intervention(s), add the following footnote. If hormonal contraception is prohibited, or if hormonal contraception efficacy 
is NOT decreased due to interaction with study intervention(s), delete the following footnote:]
c   Male condoms must be used in addition to female participant hormonal contraception.
d   If locally required, in accordance with CTFG guidelines, acceptable hormonal contraceptives are limited to those which 
inhibit ovulation. 
e   IUS is a progestin releasing IUD.
Note: The following are not acceptable methods of contraception:
-  Periodic abstinence (calendar, symptothermal, post- ovulation methods), withdrawal (coitus interruptus), 
spermicides only, and LAM.
-  Male and female condom should not be used together (due to risk of failure with friction).
08CG6Z
PRODUCT: MK-8189  93
PROTOCOL/AMENDMENT NO.: 017-04
MK-8189 -017-04FINAL PROTOCOL 21-JUL-2022
10.6 Appendix 6: Collection and Management of Specimens for Future Biomedical 
Research
1.Definitions
a.Biomarker: A biological molecule found in blood, other body fluids, or tissues that is
a sign of a normal or abnormal process or of a condition or disease. A biomarker may
be used to see how well the body responds to a treatment for a disease or condition.1
b.Pharmacogenomics: The investigation of variations of DNA and RNA characteristics 
as related to drug/vaccine response.2
c.Pharmacogenetics: A subset of pharmacogenomics, pharmacogenetics is the in fluence 
of variations in DNA sequence on drug/vaccine response.2
d.DNA: Deoxyribonucleic acid.
e.RNA: Ribonucleic acid.
2. Scope of Future Biomedical Research
The specimens consented and/or collected in this study as outlined in Section 8. 9will be 
used in various experiments to understand:
•The biology of how drugs/vaccines work
•Biomarkers responsible for how a drug/vaccine enters and is removed by [CONTACT_10489]
•Other pathways with which drugs/vaccines may interact
•The biology of disease
The specimen(s) may be used for future assay development and/or drug/vaccine 
development.
It is now well recognized that information obtained from studying and testing clinical 
specimens offers unique opportunities to enhance our understanding of how individuals 
respond to drugs/v accines, enhance our understanding of human disease and ultimately 
improve public health through development of novel treatments targeted to populations 
with the greatest need. All specimens will be used by [CONTACT_63558].
3. Summary of Procedures for Future Biomedical Researc h
a.Participants for Enrollment
All participants enrolled in the clinical study will be considered for enrollment in 
future biomedical research.
08CG6Z
PRODUCT: MK-8189  94
PROTOCOL/AMENDMENT NO.: 017-04
MK-8189 -017-04FINAL PROTOCOL 21-JUL-2022
b.Informed Consent
Informed consent for specimens (ie, DNA, RNA, protein, etc) will be obtained during 
screening for protocol enrollment from all participants or legal guardians, at a study 
visit by [CONTACT_63559] d esignate. Informed consent for future 
biomedical research should be presented to the participants on the visit designated in 
the SoA. If delayed, present consent at next possible Participant Visit. Consent forms 
signed by [CONTACT_88723].
A template of eac h study site’s approved informed consent will be stored in the 
Sponsor’s clinical document repository.
c.eCRF Documentation for Future Biomedical Research Specimens
Documentat ion of participant consent for future biomedical research will be captured 
in the eCRFs . Any specimens for which such an informed consent cannot be verified 
will be destroyed.
d.Future Biomedical Research Specimen(s)
Collection of specimens for future biomedical research will be performed as outlined 
in the SoA. In general, if additional blood specimens ar e being collected for future 
biomedical research, these will usually be obtained at a time when the participant is 
having blood drawn for other study purposes.
4.Confidential Participant Information for Future Biomedical Research
In order t o optimize the resea rch that can be conducted with future biomedical research
specimens, it is critical to link participant s' clinical information with future test results. In 
fact,little or no research can be conducted without connecting the c linical study data to 
the specimen. The clinical data allow specific analyses to be conducted. Knowing 
participant characteristics like sex, ag e, medical history and intervention outcomes are 
critical to understanding clinical context of analytical results .
To maintain privacy of information collected from specimens obtained for future 
biomedical research, the Sponsor has developed secure policies and procedures. All 
specimens will be single -coded per ICH E15 guidelines as described below.
At the clinical s tudy site, unique codes will be placed on the future biomedical research
specimens. This code is a random number which does not contain any personally 
identifying information embedded within it. The link (or key) between participant 
identifiers and this un ique code will be held at the study site. No personal identifiers will 
appear on the specimen tube.
08CG6Z
PRODUCT: MK-8189  95
PROTOCOL/AMENDMENT NO.: 017-[ADDRESS_111499] party (eg, a university investigator) designated by [CONTACT_429]. The investigator conducting the analysis will follow the Sponsor’s privacy and 
confidentiality requirements. Any contracted third party analyses will conform to the 
specific scope o f analysis outlined in future biomedical research protocol and consent . 
Future biomedical research specimens remaining with the third party after specific 
analysis is performed will be re ported to the Sponsor.
6.Withdrawal From Future Biomedical Research
Participants may withdraw their consent for FBR and ask that thei r biospecimens not be 
used for FBR . Participants may withdraw consent at any time by [CONTACT_100937]. If me dical records for the study are still available, the investigator will 
contact [CONTACT_75355] 
([EMAIL_1250]). Subsequently, the participant's specimens 
will be flagged in the biorepository and restricted to study use only. If specimens were 
collected from study participants specifically for FBR, these specimens will be removed 
from the biorepository and destroyed. Documentation will be sent to the investigator 
confirming withdrawal and/or destruction, if a pplicable. It is the responsibility of the 
investigator to inform the participant of completion of the withdrawal and/or destruction, 
if applicable. Any analyses in progress at the time of request for withdrawal/destruction 
or already performed before the request being received by [CONTACT_93336]. No new analyses would be 
generated after the request is received.
If the medical records for the study are no longer available (eg, if th e investigator is no 
longer required by [CONTACT_88692]) or the specimens 
have been completely anonymized, there will no longer be a link between the 
participant’s personal information and their specimens. In this situation, the request for 
withdrawal of consent and/or destruction cannot be processed.
7.Retention of Specimens
Future biomedical research specimens will be stored in the biorepository for potential 
analysis for up to [ADDRESS_111500]: MK-8189  96
PROTOCOL/AMENDMENT NO.: 017-[ADDRESS_111501] results are accessible only to the 
authorized Sponsor representatives and the designated study administrator research 
personnel and/or collaborators. Database user authentication is highly secure, and is 
accomplished using network security policies and practices based on international 
standards to protect against unauthorized access.
9.Reporting of Future Biomedical Research Data to Participants
No information obtained from explorato ry laboratory studies will be reported to the 
participant, family, or physicians. Principle reasons not to inform or return results to the 
participant include: lack of relevance to participant health, limitations of predictive 
capability, and concerns rega rding misinterpretation.
If important research findings are discovered, the Sponsor may publish results, present 
results in national meetings, and make results accessible on a public website in order to
rapi[INVESTIGATOR_100903]. Participants will not be 
identified by [CONTACT_88726].
10. Future Biomedical Research Study Population
Every effort will be made to recruit all participants diagnose d and treated o n Sponsor 
clinical studies for future biomedical research.
11.Risks Versus Benefits of Future Biomedical Research
For future biomedical research, risks to the participant have been minimized and are 
described in the future biomedical research informed consent.
The Sponsor has developed strict security, policies, and procedures to address participant 
data privacy concerns. Data privacy risks are largely limited to rare situations involving 
possible breach of confidentiality. In this highly unlikely situation, there is risk that the 
information, like all medical information, may be misused.
12.Questions
Any questions related to the future biomedical research should be e mailed directly to 
[EMAIL_1250].
08CG6Z
PRODUCT: MK-8189  97
PROTOCOL/AMENDMENT NO.: 017-04
MK-8189 -017-04FINAL PROTOCOL 21-JUL-2022
13.References
1.Nationa l Cancer Institute [Internet]: Available from 
https://www.cancer.gov/publications/dictionaries/cancer -terms?cdrid=[ZIP_CODE]
2.International Council on Harmoni sation [Internet] : E15: Definitions for Genomic 
Biomarkers, Pharmacogenomics, Pharmacogenetics, Genomic Data and Sample 
Coding Categories. Available from 
http://www.ich.org/products/guidelines/efficacy/efficacy -single/article/definitions -
for-genomic -biomarkers- pharmacogenomics -pharmacogenetics -genomic -data-and-
sample -cod.html 
3.Industry Pharmacogenomics Working Group [Internet]: Understanding the Intent, 
Scope and Public Health Benefits of Exploratory Biomarker Research: A Guide for 
IRBs/IECs and Investigational Site Staff. Avail able at http://i- pwg.org/ 
4.Industry Pharmacogenomics Working Group [Internet]: Pharmacogenomics 
Informational Brochure for IRBs/IECs and Investigational Site Staff. Available at 
http://i- pwg.org/
08CG6Z
PRODUCT: MK-8189  98
PROTOCOL/AMENDMENT NO.: 017-04
MK-8189 -017-04FINAL PROTOCOL 21-JUL-2022
10.7 Appendix 7: Country -specific Requirements
Not Applicable
08CG6Z
PRODUCT: MK-8189  99
PROTOCOL/AMENDMENT NO.: 017-04
MK-8189 -017-04FINAL PROTOCOL 21-JUL-2022
10.8 Appendix 8:Blood Volume Table
All ParticipantsScreening/
Baseline Intervention PoststudyTotal 
CollectionsmL Per 
CollectionTotal mL/ 
Test
Laboratory Safety Tests 2 4 1 7 6 42
HIV/Hepatitis Screen (at the 
discretion of the investigator)1 1 5 5
Blood for Genetic Analysis 1 1 8.5 8.5
Blood for Exploratory Plasma 
Biomarkers for AD 
Diagnosis1 1 18 18
Blood for MK-8189 and/or 
Metabolites Assay10 10 4 40
Blood for Plasma Donepezil 
Assay5 5 3 15
Blood for Plasma Memantine 
Assay5 5 3 15
Total Blood Volume per Participanta143.5mL
aIf additional pharmacokinetic/pharmacodynamic and/or safety analysis is necessary, additional blood (up to 50mL) 
may be obtained. 
08CG6Z
PRODUCT: MK-8189  100
PROTOCOL/AMENDMENT NO.: 017-04
MK-8189 -017-04FINAL PROTOCOL 21-JUL-2022
10.9 Appendix 9: Algorithm for Assessing Out of Range Laboratory Values
For all laboratory values obtained at prestudy (screening) visit and/or predose evaluation:
A.If all protocol- specified laboratory values are normal, the participant may enter the study.
B.If a protocol specified laboratory value is outside of the parameter(s) outlined in the 
inclusion/exclusion criteria (including a repeat if performed), the participant will be 
excluded from the study.
C.If ≥1 protocol -specified laboratory value not specified in the inclusion/exclusion criteria 
is outside the norm al range, the following choices are available:
a.The participant may be excluded from the study;
b.The participant may be included in the study if the abnormal value(s) is NCS (the 
investigator must annotate the laboratory value “NCS” on the laboratory safety 
test source document).
c.The participant may be included in the study if the abnormality is consistent with 
a pre -existing medical condition which is not excluded per protocol (eg, elevated 
eosinophil count in a participant with asthma or seasonal allergies) ,the medical 
condition should be annotated on the laboratory report .
OR
d.The abnormal test may be repeated (refer items a. and b. below for continuation of 
algorithm for repeated values).
a.If the repeat test value is within the normal range, the participant may 
enter the study.
b.If the repeat test value is still abnormal, the study investigator will 
evaluate the potential participant with a complete history and physical 
examination, looking especially for diseases that could result in the 
abnormal laboratory value in question. If such diseases can be ruled out, 
and if the abnormal laboratory value is not clinically relevant, then the 
participant may enter the study.
D.If there is any clinical uncertainty regarding the significance of an abnormal value, the 
participant will be excluded from the study.
08CG6Z
PRODUCT: MK-8189  101
PROTOCOL/AMENDMENT NO.: 017-04
MK-8189 -017-04FINAL PROTOCOL 21-JUL-2022
10.10 Appendix 10: General (Full) and Targeted Neurological Exam
The General (Full) and Targeted Neurological Examination will be performed at the time 
points specified in the Schedule of Activities (Section 1.3).
Note to the investigator: If at any time abnormalities are observed in the General or 
Targeted Neurological Exams, the Investigator should do additional examinations as 
needed based on his or her medical judgment.
The General (Full) Neurological Examination
The General (Full) Neurological Examination includes all of the modules listed below and is
intended to be a general screening examination.
MODULE 1 – MENTAL STATUS EXAMINATION
A.General Level of Arousal: Generally assess general level of alertness, attentiveness, and 
concentration throughout the interview. Regarding attentiveness, note evidence of 
impaired attention or concentration. For example, difficulty remembering or following 
instructions or distractibility may be signs of inattention.
B.Thought Processes and Language: Generally assess logic, relevance, organization and 
coherence of volunteer’s use of language throughout the interview.
C.Orientation (time, place, person)
D.Attention/Concentration
Ask the subject to count backwards from 100 by 7’s (“S erial 7’s”) or ask to recite months 
backwards or spell a [ADDRESS_111502] (e.g. “WORLD”) backwards.  
Note : to avoid learning effects, switch between tests throughout the study
E.Memory:   Test registration of 3 objects; then test immediate recall 5 minu tes later.
Grade :NORMAL or IMPAIRED and describe abnormality (for each, A to E, 
above).  Normal performance on Serial 7’s is getting to 65 with no more than one 
error. 
MODULE 2 – CRANIAL NERVE ASSESSMENT
A. II–Visual Fields and acuity
B. II, III–Pupil Size and Reactivity
C. III, IV, VI–Extraocular Movements (range of motion, smooth pursuit, saccades, 
nystagmus)
08CG6Z
PRODUCT: MK-8189  102
PROTOCOL/AMENDMENT NO.: 017-04
MK-8189 -017-04FINAL PROTOCOL 21-JUL-2022
1.Observe for nystagmus during eye movements, increased nystagmus at the end of 
gaze or other oculomotor changes (mild nystagmus at extreme s of gaze is normal). 
Note direction of nystagmus
D. V –Facial Sensation, Jaw Strength
E. VII–Muscles of Facial Expression (wrinkle brow, squeeze eyes shut, smile)
F. VIII –Auditory Acuity (assessed using a bed -side screening test e.g. by [CONTACT_100938]’s head or by [CONTACT_100939])
G. IX– Gag reflex
H. X –Swallow 
I.XI–Shoulder shrug
J.Tongue Protrusion (midline)
Score :left and right (except for G, H, J)
Grade :NORMAL or IMPAIRED and describe abnormality
MODULE 3 - MOTOR SYSTEM
A.Muscle Tone
1. Ask the volunteer to relax.
2.Flex and extend the volunteer’s elbows and at the knees (bilaterally). 
3.There is a small, continuous resistance to passive movement.
4.Observe for involuntary movement s(e.g., tremor, tics, fasciculations). Observe for 
resistance to passive movement; observe for decreased (flaccid) or increased 
(rigid/spastic) tone.
Score :left and right
Grade :NORMAL, INCREASED or DECREASED
B.Muscle Strength
1.Ask the subject to stand u p from sitting without using hands
Grade: NORMAL, IMPAIRED and describe abnormality
2.Test proximal limb strength by [CONTACT_100940].
08CG6Z
PRODUCT: MK-8189  103
PROTOCOL/AMENDMENT NO.: 017-[ADDRESS_111503] bilaterally, and compare one side to the other.
Score:left and right
Grade :5/5: normal; 
4/5: movement against resistance impaired; 
3/5: movement against gravity but not against resistance; 
2/5: visible movement but not against gravity; 
1/5: visible contraction; 
0/5: no visible activity
3.Test distal limb strength by [CONTACT_100941]’s feet; finger abduction and handgrip strength against your 
resistance.
Test bilaterally, and compare one side to the other.
Score :left and right
Grade:5/5: normal; 
4/5: movement against resistance impaired; 
3/5: movement against gravity but not against resistance; 
2/5: visible movement but not against gravity; 
1/5: visible contraction; 
0/5: no visible activity
C.Pronator Drift
1.Ask the volunteer to hold both arms straight forward with, palms up and eyes closed for 
~10-15 seconds as tolerated; watch for how well the arm position is maintained .
2.Instruct the volunteer to keep both arms still while you tap them briskly downward. The 
volunteer should normally be able to maintain extension and supi[INVESTIGATOR_20810]. Inability to 
maintain extension and supi[INVESTIGATOR_20810] (and drift into pronation) indicates an upper motor 
neuron deficit.
Score :left and right
Grade :NORMAL or IMPAIRED and describe abnormality
08CG6Z
PRODUCT: MK-8189  104
PROTOCOL/AMENDMENT NO.: 017-04
MK-8189 -017-04FINAL PROTOCOL 21-JUL-2022
MODULE 4 - REFLEXES
A.Biceps
B.Knee
Note :Other deep tendon reflexes may be tested at Investigator's discretion (e.g. elbow, 
wrist or Achilles tendon)
Score :left and right
Grade :NORMAL, INCREASED, DECREASED or ABSENT
C.Babinski
Score :left and right
Grade :NORMAL or ABNORMAL
MODULE [ADDRESS_111504] as possible. 
Score:left and right
Grade :NORMAL or IMPAIRED
Reminder : If the rapid alternate movements are disturbed, the subject will be asked to 
strike his hand on the thigh, raise the hand, turn it over and then strike the back of the 
hand down on the same place.  (This test is impaired in cerebellar disease, extra 
pyramidal disease and upper MN weakness.)
B.Point- to-Point Movements
1.Ask the volunteer to touch your index finger and their nose alternately several times.  
Move your finger about as the volunteer performs this task.
Score :left and right
Grade :NORMAL or IMPAIRED
Reminder : If the point -to-point testing is disturbed, the subject will be asked to place 
one heel on the opposite knee and then run it down the shin to the big toe.  Repeat this 
for both sides.  (Impaired tests indicate cerebellar disease.)
08CG6Z
PRODUCT: MK-8189  105
PROTOCOL/AMENDMENT NO.: 017-04
MK-8189 -017-04FINAL PROTOCOL 21-JUL-2022
C.Romberg
1.Ask the volunteer to stand with both feet together and eyes closed for 20 to 
30seconds without support.
2.Be prepared to catch the volunteer if they are unstable.
Grade :NORMAL or IMPAIRED
D.Gait
1.Ask the volunteer to walk across the room, turn and come back (assess posture, 
balance, swinging of arms and movement of the legs).
Grade :NORMAL or IMPAIRED and describe abnormality
2.Ask the volunteer to walk heel-to-toe in a straight line (tandem gait).
Grade :NORMAL or IMPAIRED and describe abnormality
MODULE 6 - SENSORY
A.Light touch sense:  cotton wisp on skin of forearms and legs, bilaterally.
B.Pin prick: safety pin touched lightly to skin of forearms a nd legs, bilaterally.
C.Temperature : warm or cool object touched to skin of forearms and legs, bilaterally.
D.Vibration:  tuning fork vibration detection in hands, feet bilaterally.
E.Position sense :  perception of thumb and toe movement, bilaterally.
F.Stereognosis :  (identify common objects placed in hand, e.g., coin, key).
Score :left and right
Grade :NORMAL OR IMPAIRED and describe abnormality (for each A to F)
Targeted Neurological Exam
The Targeted Neurological Examination , which is intended to focus on tests where drug 
effects can be seen, includes the following tests only:
MODULE 1 – MENTAL STATUS EXAMINATION
A.General Level of Arousal: Generally assess general level of alertness, attentiveness, and 
concentration throughout the interv iew. Regarding attentiveness, note evidence of 
impaired attention or concentration. For example difficulty remembering or following 
instructions or distractibility may be signs of inattention)
08CG6Z
PRODUCT: MK-8189  106
PROTOCOL/AMENDMENT NO.: 017-04
MK-8189 -017-04FINAL PROTOCOL 21-JUL-2022
MODULE 2 – CRANIAL NERVE ASSESSMENT
B. II, III – Pupil Size and Reactivity
C. III, IV, VI – Extraocular Movements (range of motion, smooth pursuit, saccades, 
nystagmus)
1.Observe for nystagmus during eye movements, increased nystagmus at the end of 
gaze or other oculomotor changes (mild nystagmus at extremes of gaze i s normal). 
Note direction of nystagmus
MODULE 3 - MOTOR SYSTEM
B.Muscle Tone
1. Ask the volunteer to relax.
2.Flex and extend the volunteer’s elbows ( may also move wrists simultaneously) and at 
the knees (bilaterally). When testing the upper limbs, do this again while the subject 
makes large repetitive movements with the opposite arm (e.g. patting the palm of the 
hand on the knee).
3.There is a small, continuous resistance to passive movement.
Score :left and right
Grade: NORMAL, IMPAIRED, or DECREASED and describe abnormality
MODULE [ADDRESS_111505] as possible. 
Score : left and right
Grade :NORMAL or IMPAIRED
Reminder : If the rapid alternate movements are disturbed, the subject will be asked to 
strike his hand on the thigh, raise the hand, turn it over and then strike the back of the 
hand down on the same place.  (This test is impaired in cerebellar disease, extra 
pyramidal disease and upper MN weakness.)
08CG6Z
PRODUCT: MK-8189  107
PROTOCOL/AMENDMENT NO.: 017-04
MK-8189 -017-04FINAL PROTOCOL 21-JUL-2022
D.Gait
2.Ask the volunteer to walk heel -to-toe in a straight line (tandem gait).
Grade :NORMAL or IMPAIRED and describe abnormality
MODULE 6 - SENSORY
A.Light touch sense :  cotton wisp on skin of forearms and legs, bilaterally.
08CG6Z
PRODUCT: MK-8189  108
PROTOCOL/AMENDMENT NO.: 017-04
MK-8189 -017-04FINAL PROTOCOL 21-JUL-2022
10.11 Appendix 11: Abbreviations
Abbreviation Expanded Term
ADME absorption, distribution, metabolism, and excretion
AE adverse event 
AIMS Abnormal Involuntary Movement Scale
ALP alkaline phosphatase
ALT alanine aminotransferase
AST aspartate aminotransferase
AUC area under the curve
BARS Barnes Akathisia Rating Scale
BDS blood drug screen
BID twice daily
BMI body mass index
BP blood pressure
CCU Cardiac care unit
CI confidence interval
Cmax maximum plasma concentration
CNS central nervous system 
CL clearance
CrCl creatinine clearance
CR complete response
CRF Case Report Form 
CRU clinical research unit
C-SSRS Columbia -Suicide Severity Rating Scale 
CSR Clinical Study Report
CTFG Clinical Trial Facilitation Group 
CYP cytochrome P450
DDI drug-drug interaction
DILI drug-induced liver injury
DNA deoxyribonucleic acid 
ECG electrocardiogram 
ECI event of clinical interest
eCRF electronic Case Report Form
EDC electronic data collection 
eGFR estimated glomerular filtratio n rate
EMA European Medicines Agency
EPS Extrapyramidal Symptoms
FDA Food and Drug Administration
FDAAA Food and Drug Administration Amendments Act
FSH follicle -stimulating hormone 
GCP Good Clinical Practice 
GI gastrointestinal
HBsAg hepatitis B surface antigen
08CG6Z
PRODUCT: MK-8189  109
PROTOCOL/AMENDMENT NO.: 017-04
MK-8189 -017-04FINAL PROTOCOL 21-JUL-2022
Abbreviation Expanded Term
HIV human immunodeficiency virus
HR heart rate
IA(s) interim analysis(ses)
IB Investigator’s Brochure 
ICF Informed Consent Form
ICH International C ouncil for Harmoni sation of Technical Requirements for 
Pharmaceuticals for Human Use
ICMJE International Committee of Medical Journal Editors
IEC Independent Ethics Committee
IND Investigational New Drug 
IRB Institutional Review Board
IUD intrauterine device
IUS intrauterine hormone -releasing system
IV intravenous
IVD in vitro diagnostic
LAM lactational amenorrh ea method
MDRD Modific ation of Diet in Renal Disease
MHIS Modified Hachinski Ischemia Scale
MMSE -[ADDRESS_111506](s)
SoA schedule of activities
SOP Standard Operating Procedures
08CG6Z
PRODUCT: MK-8189  110
PROTOCOL/AMENDMENT NO.: 017-04
MK-8189 -017-04FINAL PROTOCOL 21-JUL-2022
Abbreviation Expanded Term
S[LOCATION_003]R suspected unexpected serious adverse reaction
Tmax Time to maximum plasma concentration
t1/[ADDRESS_111507] upper limit of normal
VS vital sign s
WBC white blood cell
WOCBP woman/women of childbearing potential
WONCBP woman/women of nonchildbearing potential
08CG6Z
PRODUCT: MK-8189  111
PROTOCOL/AMENDMENT NO.: 017-04
MK-8189 -017-04FINAL PROTOCOL 21-JUL-2022
11 REFERENCES
[Bender, A. T. and Beavo, 
J. A. 2006]Bender AT, Beavo JA. Cyclic nucleotide 
phosphodiesterases: molecular regulation to 
clinical use. Pharmacol Rev 2006;58:488 -520.[03RW09]
[Grauer, S. M., et al 2009] Grauer SM, Pulito VL, Navarra RL, Kelly 
MP, Kelley C, Graf R, et al. 
Phosphodiesterase 10A inhibitor activity in 
preclinical models of the positive, cognitive, 
and negative symptoms of schizophrenia. J 
Pharmacol Exp Ther 2009;331(2):574- 90.[03RW0C]
[Grossberg, G. T., et al 
2020]Grossberg GT, Kohegyi E, Mergel V, 
Josiassen MK, Meulien D, Hobart M, et al. 
Efficacy and safety of brexpi[INVESTIGATOR_100904]'s 
dementia: two 12- week, randomized, double -
blind, placebo- controlled trials. Am J Geriatr 
Psychiatry. 2020 Apr;28(4):383- 400.[07X8NR]
[Kales, H. C., et al 2015] Kales HC, Gitlin LN, Lyketsos CG. 
Assessment and management of behavioral 
and psychological symptoms of dementia. 
BMJ. 2015;350:h369.[07WZB0]
[Marcinkowska, M., et al 
2020]Marcinkowska M, Sniecikowska J, Fajkis N, 
Pasko P, Franczyk W, Kolaczkowski M. 
Management of dementi a-related psychosis, 
agitation and aggression: a review of the 
pharmacology and clinical effects of potential 
drug candidates. CNS Drugs. 2020;34:243 -68.[07WZ9W]
[Schmidt, C. J., et al 
2008]Schmidt CJ, Chapin DS, Cianfrogna J, 
Corman ML, Hajos M, Harms JF, et al. 
Preclinical characterization of selective 
phosphodiesterase 10A inhibitors: a new 
therapeutic approach to the treatment of 
schizophrenia. J Pharmacol Exp Ther 
2008;325(2):681 -90.[03RW0F]
[Seeger, T. F., et al 2003] Seeger TF, Bartlett B, Coskran TM, Culp JS, 
James LC, Krull DL, et al. 
Immunohistochemical localization of 
PDE10A in the rat brain. Brain Res 
2003;985:113- 26.[03RW0G]
08CG6Z
PRODUCT: MK-8189  112
PROTOCOL/AMENDMENT NO.: 017-04
MK-8189 -017-04FINAL PROTOCOL 21-JUL-2022
[Smith, S. M., et al 2013] Smith SM, Uslaner JM, Cox CD, Huszar SL, 
Cannon CE, Vardigan JD, et al. The novel 
phosphodiesterase 10A inhibitor THPP -1 has 
antipsychotic -like effects in rat and improves 
cognition in rat and rhesus monkey. 
Neuropharmacol 2013;64:215 -23.[03RW32]
[Vardigan, J. D., et al 
2016]Vardigan JD, Lange HS, Tye SJ, Fox SV, 
Smith SM, Uslaner JM. Behavioral and qEEG 
effects of the PDE10A inhibitor THPP -1 in a 
novel rhesus model of antipsychotic activity. 
Psychopharmacology. 2016;233:2441- 50.[07WZ9S]
08CG6Z